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1. INTRODUCTION 
During last decades, asthma and atopic dermatitis (AD) have rapidly spread in 
many countries around the world, including Estonia [1, 2]. In majority of cases, 
these diseases are associated with recurring allergic hypersensitivity reactions to 
common environmental substances, i.e. people with asthma and AD are often 
allergic or atopic [3]. Although the prevalence of allergic diseases has increased 
dramatically during the last 50–60 years, the reasons for this are not fully 
understood. It seems that atopic diseases have mostly reached their plateau in 
western cultural area where approximately 20% of population is affected by the 
condition. However, the prevalence of allergic diseases is still rapidly 
increasing in many other parts of the world, notably in Eastern Europe where 
the „epidemic“ start was delayed as it has been clearly demonstrated by 
comparing the former West and East German populations.  
Often, there occurs the sequential development of the atopic diseases known 
as the atopic march and characterized by the progression of AD to asthma 
and/or allergic rhinitis. However, despite apparent association between AD and 
asthma, there is no definitive proof that AD is causal for the subsequent 
development of asthma. Hygiene hypothesis, as proposed 1989 by Strachan, has 
been used to explain the spread of allergic diseases associated with urbani-
zation. The hypothesis assumes that the T helper 1 (Th1) cell response is not 
induced early in life leaving the body more susceptible to Th2 induced disease. 
Testing the validity of the hygiene hypothesis has ended so far with 
contradicting research results showing that the real reasons behind allergic 
diseases might be much more complex.  
Although the family history is a strong predicting factor, especially in case 
of AD [4], genetic susceptibility cannot explain a marked increase in prevalence 
of atopic diseases in such a short time period, suggesting that our modern 
environment is supporting the development of allergic diseases. 
It is somewhat unexpected that in our immune system, where both innate and 
adaptive immune response mechanisms function with astonishing precision, a 
sub-program exists where large number of responses are misguided to usually 
non-harmful environmental substances. Understanding the immunological 
similarities and discrepancies in etiology and progression of AD and asthma 
may reveal early preventative and management strategies aimed towards 
reducing the global burden of these chronic inflammatory diseases. 
We are only beginning to understand the full spectrum of factors that in-
fluence the development of allergic diseases. Probably the most intriguing 
question is why the rise of prevalence of AD and asthma among different 
cultural populations has happened almost at the same time. It strongly indicates 
that mechanisms of these two diseases are partially overlapping. In our work, 
we explored different aspects in the molecular mechanisms associated with AD 
and asthma. We decided to use less traditional approaches to describe new 
features of these two diseases, which eventually might lead to better under-
11 
standing of common reasons of AD and asthma. In the first part of the study, we 
explored cellular responses and tested which cell types are infected by human 
rhinoviruses (HRVs) in in vitro reconstituted bronchial epithelium and human 
peripheral blood mononuclear cells (PBMCs). In the second part, we studied 
gene expression changes in the skin and keratinocytes from AD patients and 
explored a role of apoptosis of keratinocytes and functions of microRNAs 
(miRNAs) in AD. Our work describes different molecular aspects of AD and 
asthma and points out that these diseases are very complex and heterogenic 
conditions. 
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2. REVIEW OF LITERATURE 
2.1. Atopic dermatitis and asthma:  
parallels and discrepancies 
2.1.1. Epidemiology in the historical viewpoint 
AD and asthma are becoming the most common inflammatory diseases 
affecting both children and adults with prevalence rate of up to 20–30% in some 
countries [4, 5]. The prevalence of these diseases has increased dramatically 
during last 60 years, starting first from „westernized“ culture area and shifting 
nowadays into east European and other countries [4–7]. In most cases, AD and 
asthma can be considered allergic or atopic, i.e. they are associated with recurrent 
hypersensitivity to common environmental substances: allergens. The increase 
in atopic diseases has been so intensive that we are in the midst of an allergy 
pandemic [8]. As an example, among immigrants who arrive from areas with 
low incidence of asthma, asthma prevalence increases to that of the general local 
population over a considerably short time [9, 10]. Apparently, atopic and other 
“modern” diseases, for example type II diabetes are increasingly associated with 
demographic variables uncommon in earlier human generations factors such as 
Caesarean birth, formula feeding, repeated exposure to antibiotics, consumption 
of processed foods and probably some other unknown factors [11, 12].  
Before 1870, the cases of allergic diseases were almost not documented 
because of their minimal occurrence. This is still true for prehygiene societies in 
Africa nowadays. Asthma and AD prevalence started to increase around 1960s, 
first in industrialized western countries. Lately, as a new “epidemic”, there has 
been dramatic increase in peanut allergy cases during last 20–30 years (figure 1) 
[5, 6]. It is alarming that sequential changes in our lifestyle seem to bring us 
next types of allergic “epidemics”. So, to address this concern, we need to further 
deepen our understanding of the causes of allergic diseases and apparently non-
allergic forms of AD and asthma, not only to be able to relieve the symptoms, 
but to treat the causes themselves. 
The AD risk factors associated with increased prevalence of the disease are 
so-called western diet with high amounts of sugar and polyunsaturated fatty 
acids, small family size, high education level in the household, and living in 
urban settings and regions with low exposure to ultraviolet radiation and low 
humidity [8]. Among others, the strongest risk factor is a positive family history 
for atopic diseases, particularly for AD [9] for which twin studies suggests a 
heritability of more than 80% [4]. Children often develop AD during their first 
year of life (roughly 60% of cases), but for most of children, it disappears 
around age 3 years [10]. However, AD can start at any age [10, 11] and often, 
for adults, AD is a more serious condition than it is for children [12]. 
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Figure 1. Sequential rises in allergic rhinitis, pediatric asthma, atopic dermatitis and 
peanut allergy among population of Western societies during last two centuries. 
Prepared based on information from [7]. 
 
The incidence of asthma is the highest in childhood with a gradual decrease 
after adolescence. Boys have a greater risk of asthma in early childhood, whereas 
girls are more frequently affected after puberty [13]. Adult females have more 
severe asthma than males, with more hospital admissions [14–16], slower 
improvement [17], longer hospital stays [14] and higher rates of readmission 
[14–16]. 
 
 
2.1.2. Asthma definition 
“Asthma is a heterogeneous disease, usually characterized by chronic airway 
inflammation. It is defined by the history of respiratory symptoms such as 
wheeze, shortness of breath, chest tightness and cough that vary over time and 
in intensity, together with variable expiratory airflow limitation” [18]. According 
to the Global Initiative for Asthma report (GINA 2017), past definitions of 
asthma have been long and descriptive – mostly describing the types of inflam-
matory cells, hyperresponsiveness, symptoms, and the assumed relationship 
between these features [18]. On one hand, the need to simplify asthma 
definition was to simplify the process of diagnosing asthma in the clinical 
practice. On the other hand, it has been recognized now that asthma phenotype 
of a specific patient is not stable. The symptom pattern may shift, so diagnosis 
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and treatment should be reviewed regularly. For this reason, the term “asthma” 
is now deliberately used as a general umbrella term like “anemia”, “arthritis” 
and “cancer” to overcome the limitation caused by asthma heterogeneity and 
phenotype instability [19]. 
The other problem with asthma classification lies in the fact that the clinical 
phenotypes are often mixed up with the inflammatory, immune or molecular 
endotypes. The former are aimed to characterize clinical outcomes of the 
treatment and the latter are aimed to describe pathological side of the asthma 
condition. In both cases, the terminology has not been yet standardized and 
GINA initiatives are aimed to globally solve the problem. 
In the current thesis, we use the simplified (umbrella) definition of asthma. 
 
  
2.1.3. Pathophysiology of atopic dermatitis and asthma  
The primary events and key elements leading to AD and asthma are still not 
precisely known and are under heavy debate.  
One can characterize AD as an inflammatory, relapsing, noncontagious and 
itchy skin disorder. It is characterized by the presence of dry and scaly patches 
of the skin [20]. It has traditionally been regarded as a childhood disorder with 
imbalance of the immune system towards Th2 responses and exaggerated IgE 
responses to allergens, however, AD can occur as a lifelong clinical condition 
as well [21]. The AD course can be continuous for long periods or relapsing 
with repeated flare-ups [10, 11]. In about 80% of affected children, the disease 
is mild [22]. Patients who seem to be outgrown from the disease might continue 
to have sensitive hyper-reactive skin and might have recurrences after long 
symptom-free periods [11]. Usually, allergies to milk, egg and wheat resolve 
during childhood, but allergies to nuts and fish often persist [23]. When children 
become older, the sensitization is shifted towards inhalant allergens [24]. A 
subgroup of patients are sensitive to microbial antigens, often originated from 
yeast or Staphylococcus aureus [25]. Most of the children get relief from 
inflammatory skin diseases when they get older. For adults, AD might be much 
more serious condition, characterized by chronic, thick, red, lichenified plaques. 
Patients can experience acute, vesicular or oozing flare-ups. Pruritus is inten-
sive, strongly affecting daily life, sleep and activity of adult patients. In adults, 
AD affects different body parts as in infants. Commonly, hands, face and 
especially the eyelids are affected. The skin all over the body can be covered by 
inflammatory flare-ups – erythroderma. It is much more common for adult 
group of patients to develop infections and metabolic disorders which 
necessitate hospitalization [12]. 
Asthma pathology involves abnormal structural changes in the airway 
epithelium and submucosa. In the epithelium, we see the goblet cell metaplasia, 
hyperplasia and increase in epithelial mucin stores. In the submucosa, the 
subepithelial fibrosis [26–28], alterations in submucosal gland cells (increased 
gland volume), smooth muscle cells (hypertrophy and hyperplasia) [29–31] and 
Ca
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blood vessel cells (increased number of blood vessels) occur (figure 2) [32]. 
These changes in the airway may to lead to exacerbations when baseline airway 
caliber is narrowed and structural elements are altered in a manner that leads to 
exaggerated responses to inhaled exacerbating factors [33]. Concomitant 
sensitization to aeroallergens is very characteristic to the childhood-onset asthma, 
whereas adult one is less related to atopic sensitization [13].  
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Figure 2. Asthmatic airways are characterized by significant structural changes. The 
mucous hyperplasia and hypersecretion, significant basement membrane thickening, 
subepithelial fibrosis, increased number of blood vessels and enlarged submucosal 
glands and smooth muscle are characteristic for asthmatic airways and epithelium. 
Prepared according to the information from [34]. 
 
 
2.1.4. Allergic march 
Allergic march is the central hypothesis what refers to the phenomena of tem-
poral progression from the childhood AD to allergic asthma and to allergic 
rhinitis (figure 3, [35–37]). The observation that AD tends to be the first mani-
festation of these inflammatory processes is strongly supported by some 
epidemiological data [38]. The allergic march typically appears first in the skin, 
which partially might be due the weaker skin barrier of very young children 
[39], or suggesting that this site might have either a particular role in initiating 
allergic sensitization or the lowest threshold to reveal symptoms. Contro-
versially, wheezing might coincide or even precede development of skin 
symptoms [22, 40]. But, the evidences are still debated. Furthermore, even if 
16 
there is a tendency of developing asthma after AD, only one third of such 
children develop asthma later in life [41]. Thus, the risk seems to be lower than 
widely assumed. Nevertheless, there exist several possible mechanisms linking 
AD and allergic asthma. These include:  
• A systemic immune disorders with enhanced Th2 responses to allergens in 
exposed epithelium [42];  
• Barrier defects in the skin or airway epithelium that may lead to over-
stimulation of the immune cells by allergens [43];  
• a systemic defect causing immune cells to induce an allergic inflammation at 
any allergen-exposed epithelial surface [43].  
The knowledge of Filaggrin (FLG), a skin cornified envelope protein absent 
from the lung epithelium, supports the idea of “atopic march” phenomena [44, 
45]. Although controversial, AD patients with FLG loss-of-function mutations 
have increased incidence of asthma, indicating that the loss of an epidermal-
specific barrier protein can induce systemic atopy in humans [46–48]. It is 
speculated that epicutaneous sensitization with allergens might be behind the 
development of airway hyper-reactivity [46, 47, 49].  
 
Figure 3. A proposed pathway of atopic march from childhood atopic dermatitis (AD) 
to the development of asthma. Common genetic and environmental risk factors sum up 
sequentially along an atopic pathway from AD to asthma. TSLP – thymic stromal 
lymphopoietin. Prepared according to information from [35, 50] 
 
Still, to be sure that there exists a causal relationship from AD to allergic airway 
diseases, we need clear evidence that an effective intervention for AD leads to 
reduced asthma incidence. In other words, we need to have a therapy targeting 
AD in infants that prevents the subsequent development of asthma [51].  
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2.1.5. The microbiome and its role in inflammatory diseases 
The hypothesis of the atopic march as an explanation of the causal link between 
AD and respiratory allergic diseases may be erroneous. One might say that if 
AD would be a causal “entry point” for subsequent asthma and allergic rhinitis, 
then effective management of AD could possibly deter the progression of the 
atopic march, but this concept has not been proved yet. 
Recently, it has been proposed that our microbiota or more precisely its 
imbalance might be a casual factor for AD and asthma. The microbiota is a 
subgroup of all microbes (bacteria, fungi, protozoa, and viruses) that live in or 
on our body. Microbes outnumber human cells approximately 10 times. Most 
commensal microbes live in the gut, particularly in large intestine. The com-
position of intestinal bacterial communities is plastic and can change rapidly in 
response to changing environmental factors, including invasion by pathogenic 
microorganisms, antibiotic treatment and diet [52], and this tends to affect 
immune homeostasis as well.  
Beside bacteria, the microbiota includes viruses – so called “virobiota” [53]. 
It has been shown that virobiota actively shapes the composition of commensal 
bacterial population [54], thereby influencing the way the host immune system 
responds to harmful substances and organisms. For example, the microbiome 
plays important role shaping the responses of the intestinal T lymphocytes [55, 
56], directing them towards either being more pro- inflammatory or anti-
inflammatory type. In context of our work, it would be interesting to know if 
there are other factors besides direct infection how HRV might influence immune 
response of the host. 
The other way how the virobiota could impact the host immunity is by 
triggering immune responses that protect against other pathogenic viral and/or 
bacterial infections. For example, most people are infected by the herpes viruses 
during their childhood. Latent herpes infection produces the viral particles 
throughout our life. Generally, herpes virus infection, being either latent or active, 
is considered pathogenic. However, it apparently helps to protect the host from 
other viral and bacterial infections in a long run [57]. Protection is especially 
characteristic to the chronic infection, which increases the basal interferon γ 
(IFN-γ) expression and causes the activation of macrophages, which limits the 
spread of other infecting bacteria and viruses [57]. 
The nature of microbial exposure early in life appears to be important for the 
development of robust immune regulation. Disruption of either the microbiota 
or the host response can trigger different chronic inflammatory diseases and 
make individual hypersensitive to the allergens [58, 59]. 
However, similarly to the “atopic march” concept, the association between 
disruption of the skin or lung microbiota and inflammatory skin and lung diseases 
is still a mystery, and further studies focusing on the effects of the microbiota 
are needed. 
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2.1.6. Genetic predisposition 
Epidemiologic observations suggest that a western lifestyle and urbanization 
have important roles in the increasing prevalence of AD and asthma [60]. It is 
also difficult to find a genetic explanation for the observation that AD is more 
common in wealthier and more educated families [61, 62] or in the ethnic 
groups recently migrated from a country of low prevalence to a country of high 
prevalence [63]. However, despite exposure to similar environmental factors, 
only some people develop allergies and therefore, a family history is considered 
a strong predisposing factor for AD and to some extent for asthma [60].  
Common chromosomal linkages for AD and asthma have been identified on 
chromosomes 5q31–33, 11q13, 13q, 6p12.3 and 12q21.3 [64, 65]. Among these, 
Th2 type cluster of cytokines (encoding IL-3, IL-4, IL-5, IL-9, IL-13) and 
granulocyte macrophage colony–stimulating factor (GM-CSF) encoding genes 
are located on 5q31–33 [66]. Genome-wide association studies (GWASs) of 
asthma have added many more susceptibility factors. Most prominent are the 
IL1RL1/IL18R1, IL33, protocadherin 1 (PCDH1), cadherin-related family 
member 3 (CDHR3), HLA-DQ, serine protease inhibitor Kazal-type 5 (SPINK5), 
G protein–coupled receptor A (GPRA), and orosomucoid-like 3 (ORMDL3) at 
the 17q12-21 locus. However, it should be noted that GWAS method has its 
known limitations. So, these asthma-associated alleles have only small effect 
sizes. Presumably, the influence of these genes is strongly affected by other 
factors like the presence of allergens, pollution, viral infections, etc. [67]. As for 
AD, a number of factors like TLR2, TLR9, CD14, TOLLIP, MYD88, MAL, 
NOD1, NOD2 and NALP12, have been reported to be associated with the 
condition in GWAS studies. However, one must understand that the GWAS 
studies give us only the list of candidate genes which might be associated with 
these diseases. It is still critical to validate the functionality of these candidate 
genes with the other methods. 
Thus far, loss-of-function mutations in a key epidermal structural protein 
filaggrin (FLG) are thought to be as a major genetic factor for the development 
of AD and progression to AD-associated asthma [68–70]. However, most 
patients with AD do not have any FLG mutation, and up to 60% of carriers do 
not develop atopic diseases [68], indicating that FLG mutations are neither 
necessary nor sufficient to cause AD. It has been suggested that in case of 
mutated FLG, allergens reach more easily through the startum corneum and 
therefore immune cells and keratinocytes get activated [71]. During the 
development of AD and asthma, accumulation of multiple promoting genetic and 
environmental factors take place. Thus, although the rapid increases in disease 
prevalence is hard to explain by genetics, there seem to be certain set of genetic 
factors, which increase susceptibility to AD and asthma.  
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2.1.7. Immune responses in asthma and atopic dermatitis 
AD and asthma both are chronic and relapsing in their nature. Traditionally, the 
pathogenesis of allergic asthma and AD has been interpreted as immune 
dysregulation with predominant Th2 cytokines, such as IL-4, IL-5 and IL-13. 
Th2 cytokines IL-4 and IL-13 support immunoglobulin switching in B cells, 
inducing IgE synthesis and the expression of adhesion molecules and recruiting 
various immune cells into skin or lung subepithelial layer. IL-4 and IL-13 have 
a permissive effect on microbial invasion and epidermal barrier disruption [72], 
and induce spongiosis [73]. IL-3, IL-5 and GM-CSF promote bone marrow 
differentiation and maturation of eosinophils [74, 75]. IL-3 and GM-CSF induce 
basophil recruitment [76]. Lesions of AD are mostly caused by Th2 and Th22 
responses [77], to lesser extend by Th17 [78, 79] in Asian cohorts and Th1 
response in the chronic skin lesions [80]. 
Lately, it has been shown that innate lymphoid cell 2 (ILC2) and ILC3 are 
capable of mediating the development of inflammation in asthma or AD without 
allergen specific activation of T lymphocytes [81]. Furthermore, the increased 
numbers of ILC2 are found in AD lesions [82, 83]. ILCs are recently identified 
immune cells that are similar to T helper cells, but lack an antigen receptor. 
Similar to Th1, Th2 and Th17 cells, ILCs can be grouped based on cytokines 
they produce to ILC1, ILC2 and ILC3 cells. ILCs can be activated by cytokines 
and danger signals produced by other cells and thereby contribute to the 
development of Th2 type immunity in allergic AD and asthma. As ILCs have 
shown to be capable of initiating of chronic tissue inflammation without 
functional adaptive immunity, they have been associated with the development 
of non-allergic forms of asthma and AD [81, 84].  
Still, the reasons why Th2 type cytokines and immune responses are 
prevalent in asthma and AD are not well understood. It may be that immune 
programs become fixed because they are established in early life when the 
immune system is particularly plastic [85]. Type 2 inflammatory responses are 
often initiates in the airways in childhood, when viral respiratory tract infections 
and/or exposures to oxidants (such as cigarette smoke or other airborne 
pollutants) tend to activate airway epithelial cells to produce IL-25, IL-33 or 
TSLP. This initiates a pathogenic cascade, which leads to the development of 
asthma in children who are susceptible because they have pre-existing atopy, 
specific genetic risk factors in regulators of type 2 inflammation or other less 
well-understood vulnerabilities [86].  
We do not know exactly why allergic diseases, including the most common 
forms of AD and asthma, exist in the first place. The prevalent hypothesis 
suggests that Th2 type cytokines and immunity, including Th2 cells, eosinophils 
and ILC2s are aimed at the elimination of worms and parasites and that the 
allergy represents a misfiring of this response to otherwise harmful substances 
[81, 87–89]. Parasitic infections trigger similar inflammatory responses, sug-
gesting that allergy might be as a manifestation to ‘frustrated’ parasite 
elimination. 
20 
However, the majority of allergens are not helminths or their products. Most 
of the allergens are a diverse group of molecules with no apparent similarity in 
their structure or biological activity. Most often, we see in this group proteins 
associated with pollens, shellfish, nuts, animal dander, venoms and penicillin 
[90]. IgE-mediated sensitization is not the major shared mechanism driving the 
excess comorbidity of asthma and AD as it has been shown by a cross-sectional 
analysis in 12 European birth cohorts [91].  
Even Th2 type responses of the immune system are considered triggering in 
AD and asthma, the chronic inflammation in the tissues is associated with 
activation of multiple cytokines and recruitment of different types of immune 
cells, which thereby all contribute to the severity of the disease. For example, it 
has been shown that Th1 type responses are dysregulated and can be the main 
cause of the apoptosis of keratinocytes in cases of AD [92, 93]. Th1 cell-
mediated apoptosis via the Fas ligand resulted in spongiosis, which is a very 
characteristic feature of AD [93]. The keratinocyte apoptosis itself initiates 
increased expression of the factors that increase T-cell infiltration into epidermis, 
which then leads to the enhanced expression of other key elements for apoptosis, 
such as interferons and TNF receptor superfamily member 6 (FAS) [94]. In 
addition, Th1 cells in peripheral blood high in IFN-γ selectively undergo 
activation-induced cell death and skew the immune response toward Th2 cells 
in patients with AD [95], suggesting that there exist multiple pathways to 
suppress Th1 type immune responses in allergic diseases. 
 
  
2.1.8. Treatment 
AD and asthma cannot be cured at present; thus, the aims of the current 
therapies are to relieve symptoms and achieve long-term disease control. 
Present prevention and treatment of AD focus first on restoration of epi-
dermal barrier function, which is best achieved through the use of emollients, 
and use anti-inflammatory medicines like topical corticosteroids or calcineurin 
inhibitors. Also, it is important to avoid AD triggering factors [96]. After sta-
bilization of the AD condition, it is strongly suggested to continue with 
emollient treatment [97]. When topical treatment fails, systemic immuno-
suppressive therapy is sometimes the option. The most widely used agents are 
cyclosporin, azathioprine, methotrexate and mycophenolate mofetil. The use-
fulness of these general suppressors of immune responses for AD is still unclear 
[98]. During recent years, multiple specific biological treatments have been 
tested. Dupilumab is the newest very promising immunotherapeutic to improve 
the signs and symptoms of severe AD, including pruritus, symptoms of anxiety 
and depression. Dupilumab blocks the alpha subunit of the interleukin-4 
receptor (IL-4Rα), and thereby inhibits signaling of both the IL-4 and IL-13 
pathway [99].  
Similarly to the therapy of AD, current asthma treatments can in most cases 
effectively control symptoms and the inflammation, but do not affect the 
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underlying inadequate immune response. The disease-modifying drugs are almost 
missing. The current therapies mostly rely on bronchodilators, corticosteroids 
and β2-adrenergic receptor agonists that are used to treat the episodes of 
shortness of breath (dyspnea). Although a large subgroup of asthma patients has 
overactive Th2 type responses and a strong eosinophilia, the targeting of 
allergic asthma with selective therapies has not been as successful as hoped. 
However, recently among biological therapeutic agents, a monoclonal antibody 
(mAb) to IL-5 has been demonstrated to be effective in a subgroup of asthma 
patients with severe eosinophilic form of the disease [100]. The somehow 
disappointing slowness in the drug development reflects the complexity of the 
underlying pathogenic mechanisms of AD and asthma. 
 
 
2.2. miRNA in asthma and in atopic dermatitis 
Asthma and AD are characterized by tissue inflammation and changes in the 
immune system, which along with other factors is regulated by miRNAs. 
miRNAs are small non-coding RNA molecules that inhibit the translation and/or 
induce degradation of their target mRNAs. To date, more than 2000 unique 
miRNAs are found to be encoded by the human genome [101, 102] and are 
thought to modulate expression of >60% of genes [103]. MiRNAs are encoded 
either within the introns of protein-coding genes or by independent genes and 
transcribed by RNA polymerase II [104]. After transcription, mature miRNAs 
are produced through a multi-step process [105]. First, the primary transcript 
(pri-miRNA) is processed by the nuclear RNase III Drosha – DiGeorge 
syndrome critical region gene 8 (DGCR8) complex, into an approximately 65 
nucleotide hairpin precursor miRNA [106]. Pre-miRNAs are exported from the 
nucleus into the cytoplasm by exportin 5 and cleaved by the RNase III enzyme 
Dicer into a double-stranded miRNA-miRNA* duplex approximately 22 
nucleotides in length [107, 108]. This miRNA duplex is unwound by helicases 
and a mature single-stranded miRNA is incorporated into the RNA-induced 
silencing complex (RISC) [109]. The RISC complex binds to target mRNA 
through partially complementary sequence of incorporated miRNA [109, 110] 
(figure 4). 
miRNAs typically change target mRNA levels by binding to the 3′ untrans-
lated region (UTR) of mRNA transcripts [112]. This happens through comple-
mentary binding of specific seed sequence at the 5′ end of a miRNA to the 
target mRNA [113]. Sequence complementarity between the rest of the miRNA 
and the target mRNA is often quite low, allowing individual miRNAs to target 
multiple mRNA sequences and making the prediction of miRNA targets 
difficult [113–116]. MiRNA:mRNA interactions decrease protein translation 
and/or induce target mRNA degradation, resulting in reduced amount of mRNA 
and protein. 
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Figure 4. miRNA biogenesis and function. Primary miRNA transcript (pri-miRNA) is 
transcribed and cleaved to hairpin-shaped pre-miRNA, which is exported to the cyto-
plasm and further processed to miRNA duplex by Dicer. The duplex is unwound by 
helicases and a mature single-stranded miRNA is assembled into the RISC complex. 
The RISC complex typically modulates target mRNA stability or translation by comple-
mentary binding of miRNA to the 3′ UTR of mRNA. In case of full complementarity to 
the target mRNA, miRNAs also can mediate mRNA cleavage. Prepared according to 
information from [111].  
 
Among immune system-related miRNAs, miRNA-155, miRNA-21 and miRNA-
146a are very intensively studied and have been also shown to affect tissue 
inflammation and immune responses in allergic diseases. In addition to these 
three, multiple other miRNAs have been demonstrated to be dysregulated and 
affect the development of asthma and AD. At present, there have been per-
formed many miRNA expression profiling studies on samples from patients 
with asthma and AD [117, 118]. Profiling has identified tens of differentially 
expressed miRNAs in bronchial epithelial cells [119, 120], exosomes from 
bronchial alveolar lavage fluids [121] and peripheral blood samples from 
patients with asthma [122–124]. The roles of particular miRNAs in AD and 
asthma are studied less, however, in some cases the functions have been 
elucidated. For example, miRNA-19a expression has been shown to be 
upregulated in T cells from asthmatic airways, where it was shown to promote 
Th2 type cytokine production [125]. 
Patients with AD have been shown to have increased expression of miRNA-
155 in T lymphocytes and in the skin where it is induced by allergens and 
superantigens [126]. Numerous studies have demonstrated that miRNA-155 
functions as an activating factor of the innate and acquired immune responses, 
immune cell development and as a suppressor carcinogenesis [127]. As the 
presence of miRNA-155 is needed for the development and functions of Th2 
cells, it accordingly has been shown to contribute to allergic inflammation in 
animal models of airway inflammation and helminth infection [128, 129]. In the 
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immune system, miRNA-146a appears to be more important for controlling of 
Th17/Th1 responses and the function of Treg cells, but not Th2 cells [128]. 
miRNA-21 has been found to have a critical role in polarization and activation 
of Th2 cells, and it contributes to the development of allergic airway inflam-
mation in mice [130, 131]. miRNA-21 and miRNA-223 regulate development 
of eosinophils, and thereby also contribute to the development of type 2 
immunity [130, 132]. miRNA-375 is downregulated and plays important role in 
triggering the IL-13-driven epithelial responses [133]. 
In addition to the regulation of immune responses, miRNAs can influence 
the course and severity of allergic diseases through the modulation of inflam-
matory responses of the epithelial cells, such as skin keratinocytes and bronchial 
epithelial cells [134].  
 
 
2.3. Human rhinoviruses 
HRVs are large group of viral pathogens in humans. They were discovered 
1950s and for today, we know three genetically distinct HRV species – HRV-A, 
HRV-B and HRV-C (figure 5). HRV infections have typically two seasonal peaks 
in the spring and autumn all around the world. HRVs usually infect the upper 
respiratory tract (URT) with characteristics of rhinitis or nasal congestion, 
although up to 15% of patients may be clinically asymptomatic [135]. 
In the early 90s, HRV-A and HRV-B group were distinguished from each 
other serologically [136] and later, this distinction was more deeply charac-
terized using molecular analysis. HRV-C as a new rhinovirus subtype has only 
been recognized since 2009 [137]. For the moment, there are 74 HRV-A, 26 
HRV-B and at least 50 HRV-C known subtypes [138]. HRV strains are also 
classified based on the receptor they use to enter to cells. Eleven members of 
the HRV-A gain cellular entry through interaction with members of the low-
density lipoprotein receptor family (LDLR). The remaining strains of HRV-A 
and all members of the HRV-B bind to intercellular adhesion molecule 
1 (ICAM-1) [139]. The asthma susceptibility gene product cadherin-related 
family member 3 (CDHR3) has been shown to mediate HRV-C binding and 
entry [140].  
HRV is a single-stranded, positive-sense RNA virus of the Picornaviridae 
family with an approximately 7.2-kb genome enclosed in a protein capsid of 
roughly 27 nm in diameter. HRVs are non-enveloped viruses, which capsid 
consist of four viral proteins, VP1, VP2, VP3 and VP4. HRVs are assigned to 
subtypes according to the sequence of VP4/VP2 or VP1 proteins [141].  
The airway epithelium is the primary site of HRV infections in both the 
upper and the lower airways [142, 143]. Because HRV infection does not cause 
strong epithelial cytotoxicity, alterations of epithelial biology are believed to be 
the initiating events in the pathogenesis of HRV infections. In healthy indi-
viduals, HRV infection of the upper airways is the major cause of the common 
cold and spread of HRV infection to the lower airway epithelium generally is 
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very unlikely. In patients with asthma, the increased asthma symptoms can 
occur several days after peak of nasal symptoms, indicating that subsequent 
spread of HRV to lower airways might trigger acute exacerbations of asthma.  
Upon attachment to the cell, the virion is taken up by the endosomal 
pathway. Low pH in the endosomes causes uncoating of the virion and release 
of positive-sense strand RNA, consequent translation of viral proteins, repli-
cation of viral RNA through formation of negative-sense complementary 
strands that then allow transcription of further positive strands, and formation of 
new viral particles. Newly assembled viruses are released through epithelial cell 
lysis and distributed onto neighboring cells [138].  
 
Figure 5. Circle phylogram of HRV-A, HRV-B and HRV-C according the viral RNA 
(vRNA) composition. The relative position of minor group HRV1b, HRV29 (‘m’, 
LDLR) and major group HRV14, HRV16 (‘M’, ICAM-1) is shown with red/black bar. 
Prepared according to information from [144]. 
 
 
2.4. Human rhinovirus infection 
The airway epithelium is the first line of defense against HRV infections. Even 
so, most of the HRV infections appear to directly affect a small subset of cells 
and cell lysis is generally not extensive. Studies to map infected cells in the 
airways have generally found evidence of infected patches, and this corresponds 
to 1–5% infection rate of epithelial cells in vitro even after inoculation with 
high titers of virus [143, 145]. Well-differentiated epithelial cells are relatively 
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resistant to HRV infection [146]. HRV replication is enhanced when apical cells 
of well-differentiated epithelial cell cultures are either damaged or stripped away 
[147]. The epithelial barrier in asthma may be compromised and allergic inflam-
mation and exposure to pollutants may exacerbate this condition. It is therefore 
possible that a reduced barrier function in asthma could promote more severe 
HRV infections. HRV infection itself can also disrupt epithelial barrier function, 
and perhaps, this effect contributes to secondary bacterial infection [148]. 
When exposed to HRV, dendritic cells (DC), which serve as primary 
antigen-presenting cells that bring signals of infection to the adaptive immune 
system, migrate more slowly to the lymph nodes and provide less inflammatory 
signals than without viral exposure [149]. Following HRV infection, T cells 
move from the circulation to the lung [150]. It has been shown that major group 
of rhinoviruses - HRV-16 (HRV-A) or HRV-14 (HRV-B) – significantly inhibit 
T cell proliferation [151, 152]. Inhibition of T cell proliferation is dependent on 
HRV binding to ICAM1 on monocytes, indicating that the virus interferes with 
lymphocyte activation indirectly through effects on antibody presenting cell 
(APC). This reduction is greater when more DCs are exposed to the major 
group HRVs [152]. In addition to proliferation, HRV inhibits T-cell cytotoxic 
responses, but not NK cell activity [151].  
 
 
2.5. Human rhinoviruses and asthma exacerbation 
Asthma exacerbation is a complex clinical phenomenon involving a loss of 
asthma control that leads to a set of symptoms, including shortness of breath, 
wheeze, cough and sputum production. Airway narrowing during asthma 
exacerbations results not only from concentric smooth muscle contraction but 
also from mucosal edema and the formation of pathological intraluminal mucus. 
Exacerbations can range from mild to severe and can result in near-fatal or fatal 
episodes of respiratory failure. The most common cause of asthma exacer-
bations is viral upper respiratory tract infections [153]. Common causative 
viruses include respiratory syncytial virus in children and HRV in adults [33]. It 
has been shown that recurring severe HRV infections with wheezing in early 
life is the strongest predictor of asthma development later in life [154].  
The effects of HRV on asthma exacerbations are greatest in allergic 
individuals [155] and may be amplified by exposure to allergens [156] and 
possibly by exposure to greater levels of air pollutants [157]. In non-asthmatic 
subjects, virus infection is completely cleared by the host immune system 
causing only minimal cell death and often not inducing long-term immune 
memory. Interestingly, HRV infection of subjects with asthma does not usually 
provoke acute asthma symptoms [158, 159] and furthermore, most HRV infec-
tions in patients with asthma cause only upper respiratory symptoms similar to 
responses of non-asthmatic people.  
Recent studies utilizing prospective monitoring of nasal secretions of school-
aged children indicate that HRV infections are nearly ubiquitous in children 
26 
regardless of asthma [160]. Many of these infections are either asymptomatic or 
mild, even in children with asthma. This suggests that viral infections, most 
often due to HRV, are necessary but often not sufficient to cause acute exacer-
bations of asthma. Probably there are cofactors that either increase the severity 
of HRV infections, or else have additive effects on airway physiology to 
promote airway obstruction and acute symptoms of asthma [161]. 
Many findings suggest that reduced IFN responses could contribute to HRV-
induced exacerbations of asthma, but the nature and mechanisms of deficient 
IFN responses and asthma is still an area of controversy. According to some 
studies, IFN responses of PBMC [162, 163] and pDCs [164] are reduced in 
asthma. It has also been reported that HRV-induced production of IFN-β and 
IFN-λ is impaired in ex vivo cultured epithelial cells of asthma patients [165, 
166], raising the possibility that asthma is associated with a global defect in IFN 
production. However, other studies have reported that asthma does not have 
significant effects on IFN responses in cultured epithelial cells [167–169]. 
Moreover, an observational study of naturally acquired colds found similar viral 
shedding in children with vs. without asthma [169], while studies of experi-
mentally inoculated volunteers have shown both – no difference or there is a 
difference in the extent of immune responses to HRV between these two groups 
[158, 169–171]. 
Even being the major viral finding in respiratory virus-associated asthma 
exacerbation, the evidence supporting a causal relationship of HRV infection 
and asthma exacerbation is weak and mechanisms are poorly understood. 
 
 
2.6. B cell responses in atopic dermatitis and asthma 
Immunologically, atopy is recognized as an increase in the Th2 and IgE-
expressing memory/effector B cell numbers and appearance of plasma cells 
producing IgE antibodies specific to common environmental allergens. 
Although T cells are key players in the pathogenesis of AD and asthma, B cells 
are also found in the dermis of AD lesions [172] and in the airways in allergic 
inflammation [173]. B cell derived IgE contributes to the infiltration of 
eosinophils, as they express low-affinity IgE receptor FcεRII, into the epithelial 
layer of asthma patients [174]. Undoubtedly, B cell responses to common 
allergens play significant role in the development of these chronic inflammatory 
diseases.  
B cells can present antigens to CD4+ T cells and activate T cells. B cells 
interact with T cells via MHC class II molecule/T cell receptor and co-stimu-
latory molecules, as well as their ligands. Co-stimulatory molecules include 
CD40 and CD80/CD86 on B cells and their ligands, CD40L and CD28 on T 
cells. The expression of costimulatory molecule CD86 is increased on B cells in 
AD [175]. Th2 cytokine IL-4 induces immunoglobulin switching in B cells, 
resulting in IgE synthesis, which then promotes the expression of adhesion 
molecules and recruits various immune cells. B cells also produce chemokines 
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CCL17, CCL22 and IL-16, attracting T cells into the inflammatory tissue. IgE 
also contributes to IgE-mediated inflammation by stimulating FcεRI-expressing 
cells, such as mast cells and basophils. However, the role of IgE in pathogenesis 
of AD and asthma might be different: while attempts to inhibit IgE with 
omalizumab have shown heterogeneous therapeutic efficacy in AD [176], they 
are promising in reducing inflammatory symptoms in allergic asthma in case of 
patients with increased IgE [177]. 
How HRV enhances inflammatory processes in the airways, is most 
probably different from classical Th2 pathway. HRV infection of primary 
epithelial cells and epithelial cell lines is accompanied by a release of inflam-
matory mediators in vivo and in vitro, such as pro-inflammatory cytokines IL-1β, 
TNF-α, IL-8, IL-6 and IL-11, and the vasoactive peptides, bradykinin and lysyl 
bradykinin. It appears that a small number of HRV-infected epithelial cells 
release a variety of inflammatory factors. These soluble mediators are thought 
to orchestrate proliferation, chemotaxis, and activation of inflammatory cells, 
resulting in an amplification of the inflammatory process [149].  
We need to take into consideration that B cell activation might be initiated 
following engagement of the B cell receptor (BCR) by a specific antigen in 
either a T-cell-dependent (TD) or T-cell-independent (TI) manner [178]. It has 
also been suggested that B-lymphocytes may become increasingly relevant as 
antigen presenting cells when antigen load is low [179] and play important role 
in airway hyper-reactivity and airway inflammation, even without the presence 
of T-lymphocytes [180]. So, it is possible that B-lymphocytes induce asthmatic 
response without the help of T-lymphocytes [180].  
 
 
2.7. Summary of the literature 
Despite much progress, interpretation of research findings for AD and asthma 
has been difficult. Our understanding of the history of these diseases and the 
factors determining the remission and persistence of these conditions is still 
incomplete, as is the knowledge on epidemiology and molecular mechanisms 
behind clinical features. Epidermal dysfunction in AD and abnormal structural 
changes in the airway epithelium in asthma are undoubtedly among the major 
pathogenic mechanisms. However, whether these are the primary drivers, how 
exactly they affect the individual patients, and what might be the most optimal 
strategies for treatment are not yet satisfactory understood.  
The research included in the current thesis was aimed from the gaps in our 
knowledge and state-of-the-art discoveries in the field in the period from 2007 
to 2010. At that time, studies on HRV infection and asthma exacerbation were 
initiated in multiple labs to find a way to reduce the number of asthma 
exacerbations. At the same time, a few large scale array analysis studies about 
mRNA expression in the skin of AD patients had been published, however, 
because of differences in the array platforms and patient selection criteria, the 
results from those studies were not always well overlapping. Similarly, the roles 
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of some particular miRNAs in the immune system had been described, 
however, functions of particular miRNAs in allergic inflammation was almost 
fully undescribed.  
“Allergic march” is one of the intriguing hypotheses that might connect AD 
and asthma and give us an extra edge for understanding molecular mechanisms 
behind these two conditions. Another link between these two diseases is that 
they both are characterized by chronic inflammation of the epithelium and 
multiple similarities can be found in the inflammatory responses of bronchial 
epithelial cells and keratinocytes. However, in most of the cases, these two 
diseases are still studied separately. Taken together, the research performed 
within the current thesis was planned with the aim to elucidate particular 
molecular mechanisms contributing to the development of AD and asthma. 
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3. AIMS OF THE STUDY 
The general aim of the current thesis was to explore particular molecular 
mechanisms involved in progression of two chronic inflammatory diseases – 
asthma and atopic dermatitis.  
 
More specific hypotheses and aims were: 
Study I: HRVs are one of the main causes of virus induced asthma exacer-
bations. It was known that HRVs affect epithelial cells as well as immune cells, 
and that lymphocytes infiltrate into the subepithelial tissue of the airways during 
HRV infection in allergic individuals. However, the mechanisms through which 
HRVs infect and modulate the immune responses of lymphocytes were not yet 
well described. The aim of this study was to visualize the dynamics of HRV 
uptake, to describe HRV impact on molecular responses of monocytes and 
lymphocytes, and to clarify whether these cell types can be infected by HRVs. 
Study II: Goblet cell metaplasia and mucus hypersecretion are characteristic 
features of asthmatic epithelium. We hypothesized that HRV infection induces 
changes in mRNA expression of asthma candidate genes, and that different 
types of terminally differentiated epithelial cells might have variable sus-
ceptibility to HRV infection. Accordingly, we aimed to explore mRNA expres-
sion in bronchial epithelial cells from asthma patients cultured in air–liquid 
interface (ALI). In addition, we aimed to elucidate how Th2-type cytokines 
affect the differentiation of bronchial epithelial cells and HRV infection in ALI 
cultures.  
Study III: Skin inflammation in AD was known to be associated with altered 
expression of pro-inflammatory genes and activation of innate immune responses 
in keratinocytes. We hypothesized that these processes are also affected by 
miRNAs. We aimed to describe miRNA expression profiles of keratinocytes 
from AD patients, and to elucidate the role of specific miRNAs in keratinocytes 
and skin inflammation in AD using relevant cell culture and mouse models. 
Study IV: Enhanced apoptosis of keratinocytes was known to be the main cause 
of eczema and spongiosis in patients with the AD. IFN-γ was suggested to 
affect keratinocytes during chronic skin inflammation in AD. The aim of this 
study was to explore whether keratinocytes from patients with AD might exhibit 
differences in IFN-γ–induced apoptosis compared with keratinocytes from 
healthy subjects, and to describe alterations in mRNA expression in keratinocytes 
and skin from AD patients using mRNA array analysis. 
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4. METHODOLOGICAL CONSIDERATIONS 
The material and methods are described in detail in the method and supplemen-
tary method sections of published papers I–IV [181–184]. The most important 
methods and materials are also given here. 
 
 
4.1. Patient samples and cell cultures 
The patient materials, cell-lines, human primary cells and related materials are 
described in table 1. For all collected patient and control samples, we obtained 
approvals from relevant institutional ethical committees and written informed 
consents from each participant (papers I–IV) [181–184].  
PBMCs from voluntary healthy donors were used to estimate proliferation 
rates upon HRV stimulation using 3H-thymidine or carboxyfluorescein 
succinimidyl ester (CFSE) staining assay, to be infected with different HRV 
serotypes, to analyze the infection kinetics by cell imaging flow cytometry and 
to detect HRV infection centers inside B lymphocytes by in situ hybridization 
(ISH) (paper I) [181].  
Cytological airway brushings and microbiopsies of bronchial mucosa were 
used to obtain bronchial epithelial cells and to develop air-liquid interphase 
(ALI) cultures to study HRV16 replication and virus-induced changes in mRNA 
expression. Cytological brushings and microbiopsies of bronchial mucosa were 
obtained by bronchoscopy from 13 patients with a median duration of asthma of 
16 years (38% with early onset) and mostly with partially controlled (38%) or 
uncontrolled disease (30%). We also collected bronchial epithelium samples 
from seven non-asthmatic donors (aged 27–62 years; three female subjects) 
who underwent diagnostic bronchoscopy, but chronic airway disease was ruled 
out during further investigation. All donors were current nonsmokers (paper II) 
[183]. 
HeLa cells were used to propagate HRV serotypes 1b, 14, 29 and 16 and to 
estimate HRV titer according to 50% tissue culture infective dose (TCID50)/ml 
of produced viruses and to reinfect with viruses originated from infected PBMCs 
(papers I, II)[181, 183].  
Human primary keratinocytes were used to detect apoptotic cells, to perform 
miRNA and mRNA profiling using miRNA and mRNA Illumina arrays, to 
stimulate with different cytokines, to transfect with miR-146a precursors and 
inhibitors. Generation and maintenance of primary keratinocytes from 5 healthy 
subjects, 5 patients with AD, and 5 patients with psoriasis who went under 
cosmetic surgery are described previously [185, 186]. All included subjects 
were older than 18 years and did not receive systemic treatment and topical 
corticosteroids during at least 1 week before the study. Other functional experi-
ments were perfomed using commercially available pooled human primary 
keratinocytes from adult donors (Promocell) (papers III, IV) [182, 184]. 
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Table 1. Patient samples, primary cells, cell lines, viruses and mice. 
Materials Methods Paper 
PBMCs to estimate proliferation rates upon HRV 
stimulation using 3H-thymidine  
Paper I 
  to estimate proliferation rates upon HRV 
stimulation using CFSE staining assay 
Paper I 
  Infection with different HRV serotypes (HRV1b, 
HRV14,HRV16, HRV29) 
Paper I 
  to analyze the infection kinetics of different cell 
subtypes by cell imaging flow cytometry 
Paper I 
  in situ hybridization (ISH) of HRV Paper I 
cytological airway 
brushings, biopsies of 
bronchial mucosa and 
bronchial epithelium samples 
in ALI culture 
HRV infection and replication  Paper II 
to analyze HRV impact on mRNA expression  Paper II 
immunofluorescence Paper II 
HeLa cells (Ohio) to propagate HRV serotypes 14, 16, 1b, and 29 Paper I 
  to estimate HRV titer Paper I 
  to reinfect with viruses originated from infected 
PBMCs  
Paper I 
primary keratinocytes from 
AD patients and controls 
(from L. Kemeny, University 
of Szeged) and commercial 
human primary keratinocytes 
(Promocell) 
apoptosis analysis  Paper IV 
miRNA and mRNA expression analysis using 
Illumina arrays and RT-qPCR  
Papers III, IV
to stimulate with different cytokines  Papers III, IV
to study the effect of miR-146a after transfection 
with miR-146a precursors or inhibitors 
Paper III 
skin biopsy specimens from 
AD patients and controls 
mRNA and miRNA expression analysis, Western 
blot, laser microdissection, immunohistochemistry 
and immunofluorescence 
Papers III, IV
DyLight650-labelled 
HRV1b, HRV16; from S.L. 
(Johnston lab, Imperial 
College London) 
to measure the kinetics of HRV attachment to 
different PBMC cell types 
Paper I 
ultraviolet inactivated 
HRV1b and HRV16 
negative control in HRV experiments Paper I 
HRV1b to detect HRV replication centers in B 
lymphocytes by ISH 
Paper I 
HRV16 to infect ALI cultured HBECs Paper II 
miR-146a–/– mice in 
C57BL/6J background and 
C57BL/6J (B6) wild type 
mice (The Jacksons 
Laboratory) 
to study the effect of miRNA–146a in MC903-
dependent mouse model of AD  
Paper III 
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Skin biopsies (diameter: 4 mm) were collected from 10 patients with chronic 
AD (5 females, 4 males, age 18–42) and 9 healthy subjects (4 males, 5 females, 
age 19–43). All patients had experienced 6- to 14-day-long severe exacerbation 
of the disease. None of the patients had been treated with systemic antihista-
mines or topical corticosteroids for at least 1 week before inclusion in the study.  
 
 
4.2. Apoptosis detection 
Generation and maintenance of primary keratinocytes for apoptosis assays was 
performed as described previously [185, 186]. In brief, keratinocyte viability 
was measured by means of flow cytometry after staining with 7-amino-
actinomycin D (7-AAD) and annexin V (Beckman Coulter) according to the 
manufacturer’s protocol. Viability represents the percentage of annexin V- and 
7-AAD-negative cells. Cells that were early apoptotic were annexin V-positive, 
late apoptotic and necrotic cells were annexin V and 7-AAD-positive]. 
 
 
4.3. Generation of HRV stocks 
HRV serotypes 1b, 14, 29 and 16 were propagated in Ohio HeLa cells using 
standard protocol [160]. Virus stocks were titrated by infecting HeLa mono-
layers with serially diluted HRV and assessing cytopathic effect to estimate 
their 50% tissue culture infective dose TCID50/ml by Kremser method. The 
identities of all HRVs were confirmed by neutralization using serotype-specific 
antibodies (ATCC). TCID50/ml was expressed as multiplicity of infection 
(MOI) based on TCID50; 0.1 ml of a TCID50 virus of 1e7 per ml on 1e6 cells 
would be an MOI of 1.  
 
 
4.4. Ultraviolet inactivation of virus and ‘Mock’ solution 
UV-inactivated virus was prepared by irradiating the virus suspensions in a 24-
well tissue culture dish on ice for 10 min with a 75 W UV source (254 nm) at a 
distance of 5 cm. Treatment resulted in the complete loss of infectious titer as 
estimated by titration assay. To produce ‘mock’ solution, Ohio HeLa cells were 
cultured as for virus production, but without viruses to the culture. 
 
 
4.5. Labeling of HRV with DyLight650 
We developed a new method to visualize HRVs and measure the kinetics of 
infection based on labeling of viruses with DyLight650 (Thermo Scientific). 
First, media component in the virus stock (both active and UV inactivated) 
solutions was replaced with PBS by dialyzing it 2 times for 4 h at 4°C with cold 
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PBS (pH 7.0). For dialysis, membrane MWCO of 6–8 kDa Spectra/Por Dry 
Standard RC Dialysis Tubing (Spectrum Labs) was used. For the labelling, 
1 mg of DyLight650 NHS Ester was added to 15 ml of virus samples, mixed, 
and stained at RT for 1 h protected from light. Labeled and starting nonlabeled 
virus solutions were titrated by endpoint titration assay in parallel and stored at  
–80°C. Labeling caused the drop in virus infectivity 5 times when compared 
with the starting nonlabeled virus (paper I, [181]). 
 
 
4.6. Isolation and culturing of PBMCs 
PBMCs were obtained from heparinized whole blood by Biocoll (Biochrom 
KG) density gradient centrifugation. The cells were washed three times with 
PBS (0.02% EDTA added) and suspended in RPMI 1640 medium supple-
mented with L-glutamine (2 mmol/l), MEM vitamin, penicillin (100 U/ml), 
streptomycin (100 lg/ml), kanamycin, nonessential amino acids, sodium 
pyruvate (Life Technologies), and 10% heat-inactivated fetal calf serum (FCS; 
Invitrogen, Cat.No. 10082147). 
 
 
4.7. Proliferation assay with 3H-thymidine 
After 5 days of stimulation with unlabeled active or UV-inactivated or without 
viruses (mock) in triplicate, PBMCs were pulsed for 8 h with 3H-thymidine, 
harvested with a Tomtec plate washer, and counted on a Betaplate counter. The 
results were expressed as a stimulation index (SI). 
 
 
4.8. CFSE labeling of PBMCs 
PBMCs were washed in PBS twice and suspended in 10 ml PBS containing 5% 
FBS. CSFE (from 10 mM stock and at the final concentration of 5 μM) was 
added to the tube and immediately shaken vigorously. Labeling of PBMCs was 
done promptly 5 min at room temperature in the dark. The cells were washed 
three times in PBS supplemented with 5% FCS. Thereafter, complete RPMI 
1640 (cRPMI) media were added and the cells were transferred to a cell culture 
incubator (at 37°C under 5% CO2) for further experiments. 
 
 
4.9. Flow cytometry and cell sorting 
For the expression of surface markers, the cells were stained with the following 
antibodies: CD3-FITC, CD16-FITC, CD19-ECD, CD19-PC5 (all from Beckman 
Coulter), CD4-PE/Cy7, CD14-APC/Cy7, CD19-Brilliant Violet 510, CD19-
APC/Cy7 (all from BioLegend), TRAIL-R2-FITC (R&D Systems) and FN14-
FITC (eBioscience). Matching isotype controls were used as negative controls. 
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Samples were measured with a FACSAria II instrument (Becton Dickinson) or 
Gallios flow cytometer and analyzed using Kaluza software (Beckman Coulter). 
Dead cells were excluded based on staining with the eFluor 450 dye. Before 
imaging flow cytometry, CD14+ cells were sorted out from the rest of the cells 
according to the CD14-APC/Cy7 signal. To obtain purified CD14+ cells, we 
excluded from this cell population eFluor 450-positive cells as dead cell 
population.  
 
 
4.10. Imaging flow cytometry of PBMCs infected by HRV 
For tracking HRV infection capacity, DyLight650 labeled viruses were used to 
infect PBMCs followed by imaging flow cytometry (Amnis). To avoid over-
lapping of the APC/Cy7 signal with the side scatter signal on the ‘Image-
Stream’, the monocytes were sorted out with the cell sorter FACSAria (Becton 
Dickinson) before taking images on the ‘ImageStream’. Signal strength was 
compensated between different channels according to the manufacturer’s proto-
cols. Flow speed was stabilized before collecting 30 000 events and 40x magni-
fication was used for taking images. Data were analyzed using ‘Ideas’ software 
(Amnis) (paper I, [181]). 
 
 
4.11. QuantiGene ViewRNA in situ hybridization for vRNA 
A very specific and sensitive method for HRV viral RNA in situ hybridization 
was developed in cooperation with Affymetrix (Cat.No. VF1-12634). Shortly, 
PBMCs were added on top of the polylysine-coated microscopic slides and in-
fected with HRV or controls for 5 days. Before cell fixation, media was care-
fully replaced with PBS. Thereafter, the cells were fixed with 4% paraformalde-
hyde (PFA) and washed with PBS and dehydrated with ethanol at increasing 
concentrations (50%, 70%, and 100%). Slides were submerged in 100% ethanol 
at 20°C for storage. Before further analysis, the cells were rehydrated using 
decreasing concentrations of ethanol (70% and 50%) and washed with PBS. 
ISH was performed using QuantiGene ViewRNA protocols designed to detect 
specifically 20-nucleotide-long sequences in HRV vRNA of which15 sites were 
used for amplifying the signal and 5 sites were used for blocking the nonspecific 
binding. The cells on the slides were permeabilized with working detergent 
solution (Affymetrix) and hybridized for 3 h at 40°C with custom designed 
QuantiGene ViewRNA probes against positive strand HRV1b and human actin-
beta. Unbound probes were flushed out with wash buffer (Affymetrix). The 
bound probes were amplified through PreAmp (Affymetrix) hybridization for 
1 h at 40°C, followed by Amp (Affymetrix) hybridization for 1 h at 40°C. 
Labeled probes (Affymetrix) targeting the individual probe types were added 
for 1 h at 40°C. The slides were covered in 4’,6-diamidino-2-phenylindole 
(DAPI)-containing mounting medium and examined using an LSM 510 con-
focal microscope (Zeiss) (paper I, [181]). 
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4.12. Detection of infectious HRV virions in PBMCs by qPCR 
PBMCs were infected with unlabeled-HRV16 at MOI 10 and incubated for 24 h 
at 37°C in tissue culture incubator using regular cell culture conditions. Then, 
the PBMCs were washed three times with prewarmed PBS and added at a 
number of 800 000 cells per well (500 μl volume) in a 48-well plate seeded with 
HeLa cells. Uninfected HeLa cells were seeded in these wells 24 h before and 
were growing in log phase. In the ICAM-1-blocking condition, anti-ICAM1-Ab 
was added to HeLa cells at the concentration of 1 μg/ml 2 h before infected 
PBMCs were added. Three days after the addition of PBMCs, HeLa cells were 
washed thoroughly to remove nonadherent PBMCs and RNA was isolated from 
HeLa cells using the RNeasy Micro Plus kit (Qiagen). The expression of 
negative and positive strands of viral RNA was analyzed by RT-qPCR. 
 
 
4.13. Isolation of Human Bronchial Epithelial Cells and  
Air–Liquid Interface Cultures  
Human bronchial epithelial cells (HBECs) were isolated by enzymatic digestion 
of biopsy material with pronase and DNase (Sigma-Aldrich) and cultured in 
flasks coated with type IV collagen (Sigma-Aldrich) in supplemented bronchial 
epithelial growth medium (Lonza). Second-passage cells were seeded onto 
collagen-coated inserts (Costar) at a density of 1.0 x 105 cells/cm2 and cultured 
in air–liquid interface (ALI) system using a 1:1 mixture of bronchial epithelial 
growth medium and Dulbecco’s modified Eagle’s medium (Lonza) enriched 
with 75 nM all-trans-retinoic acid (Sigma-Aldrich) as previously described 
[147]. To induce mucus metaplasia, cells were treated with IL-13 (5 ng/ml) 
(Sigma, France) for 8 days, with the addition of IL-4 (5 ng/ml) (R&D Systems 
Europe Ltd., UK) in the last 4 days. Aliquots of the bottom well culture medium 
were collected, spun, and stored at –80°C for eicosanoid measurements. Cells 
were harvested and lysed with TRI-reagent (Sigma-Aldrich) for RNA extraction 
or fixed in 4% PFA for immunofluorescence staining. 
 
 
4.14. mRNA expression analysis of HRV16 infected  
human bronchial epithelial cells 
Cytological brushings and microbiopsies of bronchial mucosa were obtained by 
bronchoscopy from 13 donors with asthma and from seven non-asthmatic donors. 
All donors were current nonsmokers. Bronchial epithelial cells were isolated, 
cultured in ALI system and mucus metaplasia was induced before infection with 
HRV16 (see 4.13). We washed epithelial cells surfaces to ensure optimal 
attachment of the virus. After 2 hours of early incubation with HRV16, cells 
were extensively washed to remove the unbound viruses. After 48h, epithelial 
cells were collected for transcriptome analyses. 
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Total RNA was isolated using Total RNA Kit (A&A Biotechnology) and 
reverse transcribed (HC Reverse Transcription KIT; Applied Biosystems). 
Relative mRNA expression was quantified using a predesigned Low-Density 
Array (Applied Biosystems) and 7900HT Fast Real Time PCR System (Applied 
Biosystems). Expression of selected genes (e.g., cilia transcriptome genes EZR 
or SYK) was assessed by SYBR green-real time (iCycler) using target specific 
primers (TIB Molbiol). A full list of analyzed genes is presented in Table E1 in 
the online supplement (paper II [183]). Data were normalized to 18S rRNA, and 
relative quantities (RQ) of individual transcripts were calculated using a 2-ΔΔCT 
method [187]. In volcano graphs, log2 RQ values (biological significance) were 
plotted against –log10 P values (statistical significance) estimated using a t test. 
A 2-fold change in the expression was considered biologically significant 
(log2 RQ < –1 or > 1). 
 
 
4.15. miRNA and mRNA expression profiling,  
pathway analysis and miRNA target prediction 
(keratinocytes and skin samples) 
A total RNA from keratinocytes or skin from AD patients and control subjects 
(3 donors in each group) were used for miRNA and mRNA profiling with 
Illumina miRNA Universal-16 and HumanHT-12 Expression BeadChips. 
miRNA and mRNA Illumina arrays were carried out at the Core Facility at the 
Department of Biotechnology, University of Tartu, using 500 ng of total RNA 
per each sample. The data were analyzed with GenomeStudio 2011.1 Gene 
Expression Module using average normalization for miRNA data and Illumina’s 
custom rank invariant method for mRNA arrays. 
Genes were considered to be expressed at detection P < 0.05 and differentially 
expressed at differential P < 0.05. Further analyses and visualizations were 
performed using Microsoft Excel and Multi Experiment Viewer 4.6.1 or 4.6.2. 
Unsupervised hierarchical clustering was done using Euclidean distance and 
average linkage analysis. Heatmaps were generated using Multi Experiment 
Viewer 4.6.1. Log2 values of expression levels that were mean-centered across 
all of the samples for each gene are presented. Color scale from green/blue (lower 
expression) to red (higher expression) represents deviation from the mean (black). 
Pathway analysis was performed with g:Profiler (http://biit.cs.ut.ee/gprofiler), 
which retrieves the most significant gene ontology groups and Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) pathways, and enables one to estimate 
the significance of the search results by calculating enrichment P value using 
Fisher 1-tailed test. miRNA targets were predicted using Targetscan 6.2 [103, 
188]. 
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4.16. Isolation of RNA, cDNA synthesis, and qRT-PCR 
(human keratinocytes, human and mouse skin samples)  
In papers III and IV, a total RNA was extracted using miRNAeasy Mini Kit 
(Qiagen). Homogenization of the human and mouse skin, epidermis, and dermis 
samples was done either by Ultra-Turrax T8 (IKA Labortechnik) or Precellys 
24 (Precellys) homogenizer or gentleMACS diccociator (Miltenyi Biotec). 
cDNAwas synthesized from 200 to 900 ng of total RNA using oligo-dT and 
reagents from Thermo Scientific SuperScript III Reverse Transcriptase (Invitro-
gen) or reverse transcription reagents with random hexamers (Fermentas) 
according to manufacturers’ protocols. RNA concentration and quality were 
assessed with NanoDrop ND-1000 and Agilent 2100 Bioanalyzer. TAQMAN 
(Applied Biosystems) or SYBR/Rox master mix (Bio-Rad Laboratories or Solis 
BioDyne) and ABI Prism 7900 were used for qRT-PCR. The relative gene 
expression levels were normalized to mouse or human EF1A levels and calcu-
lated using the comparative Ct (ΔΔCt) method (Life Technologies). The mean 
level of control experiments or control group was equalized to 1. miRNA qPCR 
was carried out by using TaqMan micro-RNA Assays (Life Technologies) and 
were normalized to Let-7a. All PCR primers were designed with the assistance 
of Primer 3 software, and were ordered from Microsynth (Balgach). 
 
 
4.17. RT-qPCR primers 
Primers used in papers III and IV were designed with the assistance of Primer 3 
and ordered from Microsynth. [182, 184]. 
 
Gene Forward Reverse 
ANXA5 AGGCTTGGGCACAGATGAGGAGA GCTGCAGAGATTTCCTGGCGCT 
ADM CTCTTAGCAGGGTCTGCGCTTCG CCGACGCGACATCCAACCGA 
CARD10 AGTGTGCCCAGCGGAAAGCC GATGGCCCGGATCCTGCTGC 
CCDC109B CGCCCCAGGTTTTGCGTGTGA TTTCATCAGGTGGCACCACGGTACT 
CCL8 AGGGACTTGCTCAGCCAGATTCAGT TCTTGTGTAGCTCTCCAGCCTCTGG 
CCL5 AGTCGTCTTTGTCACCCGAAA TCTCCATCCTAGCTCATCTCCAA 
EF1Aex7-8 CCACCTTTGGGTCGCTTTGCTGT TGCCAGCTCCAGCAGCCTTCTT 
IRAK1 CACCTTCAGCTTTGGGGTGGTAGTG CCAGCCTCCTCAGCCTCCTCT 
IFI35 GGAACGGAGGTGGCGATGTGG CAGACGCTGAGCCACTCCATCC 
IFITM1 CAACACCCTCTTCTTGAACTGG GCCGAATACCAGTAACAGGATG 
IFITM2 GTTCAACACCCTCTTCATGAACA GACGACCAACACTGGGATGAT 
IL8 GCAGCTCTGTGTGAAGGTGCAGTT TTCTGTGTTGGCGCAGTGTGGTC 
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LYN  AGCTCGTGAGGCTCTACGCTGT CAGCAAACTGCCCTTGGCCATG 
RAB39 GGGAGGTTCCCCTGAAGGATGCT GGGTGGGATCTGGCGGCTGAT 
PCSK9 ACGTCCTCACAGGCTGCAGC TTGGGCTGACCTCGTGGCCT 
NOD2 TGAGGTGGCTCAGCCTGGTGG TGCCAGCATCAGTGCCAAGGC 
hUBD CAGAGATGGCTCCCAATGCT CGCTGTCATATGGGTTGGCA 
mCARD10 GCGAGGTCTACCCCATTGTC CAACAGGCCCCTGATCTCAC 
mCCL24 TCCCAAGGCAGGGGTCATCTTCA TGCCTCTGAACCCACAGCAGC 
mCCL5 GCCTCACCATATGGCTCGGACAC TTGACGTGGGCACGAGGCAG 
mCCL8 GGGCCAGATAAGGCTCCAGTCACC TCAGCACCCGAAGGGGGATCT 
mCXCL2 TGAACAAAGGCAAGGCTAACTG CAGGTACGATCCAGGCTTCC 
mEF1A CGGCAGTCGCCTTGGACGTT CGGTGGTTTTCACAACACCTGCGT 
mIFNg TGCCAAGTTTGAGGTCAACAACCCA ACAGCTGGTGGACCACTCGGA 
mIL1b AGCTTCCTTGTGCAAGTGTCT TGGGGTCCGTCAACTTCAAA 
mIL4 CAGGAGAAGGGACGCCATGCAC GCGAAGCACCTTGGAAGCCCT 
mIL6 ACTTCACAAGTCGGAGGCTT TGCCATTGCACAACTCTTTTCTC 
mIRAK1 TGTGAGGACACAAGGTGCAA TAGGCTGGGTGCTTTTCAGG 
mTSLP ATCGAGGACTGTGAGAGCAAGCCAG GTGAAGGGCAGCCAGGGATAGGA 
mUBD TTCTGTCCGCACCTGTGTTG GAGACCTTGGTTTGGGACCT 
mLor TCCCTGGTGCTTCAGGGTAAC TCTTTCCACAACCCACAGGAG 
 
 
4.18. Mouse AD model 
miR-146a–/– mice in C57BL/6J background and C57BL/6J (B6) wild type 
(WT) mice were purchased from the Jackson Laboratory (Bar Harbor). The 
mice were maintained and bred in the animal facility at the Institute of 
Molecular and Cell Biology, University of Tartu, in accordance with the 
institute’s regulations. Nine- to 10- week-old female mice were used for the 
experiments. Animal experiments were approved by the Animal Ethics Com-
mittee of the University of Tartu. MC903 (calcipotriol hydrate, C4369, Sigma-
Aldrich) was dissolved in EtOH and topically applied on mouse ears 
(1 nmol per ear) on every other day 10 times starting at day 0. As vehicle 
control, the same amount of EtOH was applied. Analyses of the ear biopsies and 
lymph nodes were performed on day 19. 
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4.19. Immunofluorescence 
For B lymphocytes, immunofluorecence (IF) was performed after ISH by incu-
bating microscope slides with PBMCs for 30 min with anti-human CD20 
(MS4A1 Rab-MAb, rabbit anti-human, Epitomics 1632-1, Epitomics) or with 
anti-rabbit polyclonal antibody (IC control). Then the slides were washed and 
further incubated for 30 min at RT in dark with secondary antibody (Alexa 
Fluor 488 goat anti-rabbit IgG (H + L), A11034; Invitrogen). Then, slides were 
mounted with VectaShield mounting medium containing DAPI, dihydro-
chloride (Vector Laboratories) and analyzed with a Leica Fluorescence micro-
scope (Leica Microsystems) (paper I, [181]). 
Airway epithelial cells (paper II, [183]) were permeabilized with 0.3% 
Triton-X100, blocked (goat IgG and FCS), and stained with mAb for MUC5AC 
to detect goblet cells, β-Tubulin-IV to mark cilia (all from Sigma-Aldrich, 
USA), or HRV-capsid viral protein-2 (VP2) (mAb recognizing HRV capsid 
protein VP2 and its precursor) to detect HRV-infected cells. Cells were treated 
with secondary goat anti-mouse IgG antibodies conjugated with Alexa Fluor 
488 or Alexa Fluor 568 and Hoechst 33342 (all from Molecular Probes, USA). 
 
 
4.20. Statistical analysis 
Statistical tests were performed using GraphPad Prism 5.0 (GraphPad Software) 
and ‘R’ (R Core Team, 2017), specifically the ggplot2 package (H. Wickham – 
author). Statistical significance was determined using the 2-tailed Student’s t-
test or one-way ANOVA with Bonferroni’s multiple comparison test (signi-
ficance level is α/m, where α is the desired overall α level and m is the number 
of hypotheses) to pinpoint the difference between two groups in multiple 
selections (paper I, II, IV [181–183]). 
For apoptosis, viability, and proliferation assays, statistical analysis between 
paired conditions (non-stimulated and stimulated keratinocytes from the same 
subject) was performed by using the Wilcoxon signed-rank test (paper IV 
[182]). The comparison between the groups in paper IV was performed with 
nonparametric Mann-Whitney U tests. Statistical analysis for paper III qRT-
PCR and cytokine measurement results was performed by the unpaired Student 
t test (paper III [184]).  
The results were considered significant at P value of less than 0.05 and 
highly significant at P values of less than 0.01 and 0.001 (papers I – IV [181–
184]). 
Statistical analysis of Illumina miRNA and mRNA array results and pathway 
analysis are described in subsection 4.15. 
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5. RESULTS AND DISCUSSION 
5.1. Human rhinoviruses can attach or enter to monocytes, 
CD4+ and CD8+ T cells and B cells.  
The principal site for HRV replication is respiratory epithelium. However, the 
capacity of HRVs to directly infect immune cells and to modulate immune 
responses has been studied less. Levandowski et al. [189] have demonstrated 
that the total lymphocyte count of infected individuals was significantly reduced 
on day 3 after the challenge with HRV. The reduced number of lymphocytes in 
the circulation can be at least partly explained by a massive lymphocytic and 
eosinophilic infiltration into the infected tissues. This cell infiltration to bronchial 
mucosa might be responsible for changes in airway hyper-responsiveness and 
asthma exacerbations [190]. Previously, it has been shown that under certain 
conditions (especially timing and choice of ‘right’ viral concentration are 
important), HRV is able to infect alveolar macrophages in vivo [191], as well as 
T cells [192] and Ramos cells (B-cell line) in vitro [193]. 
To study the dynamics of virus attachment and uptake by different PBMC 
populations, we used virus particles labeled with DyLight650 (paper I) [181]. 
We observed that monocytes internalize both HRV and UV-HRV (UV-inacti-
vated) viruses (figure 6A, B), which indicates that the uptake of HRV particles 
by monocytes does not occur only via HRV-specific receptor-mediated infec-
tion. B and T lymphocytes had distinct attachment and/or internalization pattern 
in the case of functional virus and no signal with UV-treated viruses was 
detected. There was a lag time of around 8 h before HRV was detected in B, 
CD4+ and CD8+ T cells. In the case of CD4 T cells, the DyLight650-labeled 
virus signal overlapped CD4 signal that points to the attachment of virus to CD4 
(figure 6B). Our results were concordant with the previously reported results 
about the attachment of HRV to different types of leukocytes [194]. This study 
looked in more detail at the T-cell part and showed that T-cells got activated by 
HRV induction with the maximum at HRV titer MOI = 1.0 according to a CD69 
as T-cell activation marker. In study I, we observed activation of B-cells at 
MOI = 1–10.0. It might be that for the activation of lymphocytes, the con-
centration of HRV must be in a certain range, raising the interesting question as 
to why the exact viral concentration is important. It is possible that in allergic/ 
asthmatic individuals, HRVs infect not only lower respiratory tract (LRT) 
epithelial cells, but also underlining infiltrating immune cells in the inflamed 
epithelium, which ultimately may lead to a strong nonspecific induction of  
B-cell proliferation in bronchial tissue. This might lead to a rapid increase in the 
total serum IgE, as observed previously [195] and therefore can provide a 
synergistic link between allergy, HRV infection and exacerbation of asthma 
[160]. 
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Figure 6. Analysis of DyLight650‐labeled HRV1b uptake by PBMCs. PBMCs were 
cultured in the presence of DyLight650‐labeled HRV1b or HRV16 at MOI = 1.0 and 
MOI = 10 or ‘mock’ and analyzed at the indicated time points by flow cytometry (A) or 
imaging flow cytometry (B). The UV‐treated viruses were used at MOI = 10. (A) Data 
are mean with CI 95% of 6 donors. (B) Imaging of HRV1b interactions with mono-
cytes, T cells, and B cells. Bright‐field (BF) image shows the shape of cells. CD14+ 
monocytes were sorted out 1h after incubation with the virus by cell sorter and then 
analyzed for DyLight650‐labeled HRV1b (red). T lymphocytes were analyzed for 
surface markers using anti‐CD3 FITC (green) and anti‐CD4 PE/Cy7 (purple) and for 
DyLight650‐labeled HRV1b (red) 24 h after incubation with the virus. B lymphocytes 
were analyzed with anti‐CD19 FITC (green) for DyLight650‐labeled HRV1b (red) after 
24h incubation with the virus (paper I) [181]. Reprinted with permission of the John 
Wiley and Sons. Copyright © 2017 John Wiley and Sons. Aab A, Wirz O, van de Veen 
W, Söllner S, Stanic B, Rückert B, Aniscenko J, Edwards MR, Johnston SL, Papa-
dopoulos NG, Rebane A, Akdis CA, Akdis M. 2017. Human rhinovirus forms viral 
replication centers in B cells and induces the proliferation of B lymphocytes. Allergy. 
2017 Feb;72(2):232–243. doi: 10.1111/all.12931 
 
As HRV infects primarily URT and LRT epithelial cells, there are relatively 
few publications addressing the question that under certain circumstances HRV 
might infect other cell types. Recently, it has been shown that HRV can infect 
macrophages and T-cells [191, 192], so we focused our studies on another 
lymphocyte subgroup – B cells, with which we detected interaction of HRV1b 
and HRV16 (figure 6A). 
To determine whether HRV can infect B cells, we used ISH for viral RNA 
(vRNA). Indeed, we were able to detect vRNA in B cells, whereas the size of 
the vRNA signal found in B cells indicated that these clusters were viral repli-
cation centers (figure 7).  
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Figure 7. Visualization of HRV1b vRNA with in situ hybridization (ISH). PBMCs 
were cultured with HRV1b and subjected to ISH analysis on the 5th day. HRV1b vRNA 
is designated with green, human beta‐actin mRNA with red, DAPI with blue, and 
anti‐CD20 (purple arrow) as the marker for B cells with purple color. Representative 
images of 4 donors on 5th day are presented. White arrows indicate the vRNA signal. 
Bars indicate 10 μm (paper I) [181]. Reprinted with permission of the John Wiley and 
Sons. Copyright © 2017 John Wiley and Sons. Aab A, Wirz O, van de Veen W, Söllner 
S, Stanic B, Rückert B, Aniscenko J, Edwards MR, Johnston SL, Papadopoulos NG, 
Rebane A, Akdis CA, Akdis M. 2017. Human rhinovirus forms viral replication centers 
in B cells and induces the proliferation of B lymphocytes. Allergy. 2017 Feb;72(2):232–
243. doi: 10.1111/all.12931 
 
One of the main findings of us was the observation that HRVs were able to 
induce B-cell proliferation. In our experiments, the rate of proliferation was 
time-, HRV type-, and dose- dependent (figure 8, figure 1A–D (paper I) [181]). 
This ability of HRVs was not known before, but not surprisingly, other 
picornaviruses, such as poliovirus and Coxsackie virus, efficiently induce the 
proliferation of B cells even independently from T helper cells [196]. It is 
known that T-cell-independent antibody response results from extensive B-cell 
receptor cross-linking by the highly organized, repetitive picornavirus virion 
structure and is postulated to be generally characteristic of picornaviruses 
viruses [196], as is HRV. So, it is possible, that HRV’s ability to infect B-cells 
in vitro is not the reason for the proliferation of these cells, but separate events, 
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such as crosslinking of B-cell receptors induces the B-cell proliferation. It 
would explain why we need the certain concentration of HRV particles to 
induce the cell proliferation. It has also been suggested that B lymphocytes may 
become increasingly relevant as antigen-presenting cells when antigen load is 
low, even without the help of CD4+ T lymphocytes [179]. It is possible that in 
allergic/asthmatic individuals, HRVs infect not only LRT epithelial cells but 
also underlining infiltrating immune cells in the inflamed epithelium, which 
ultimately may lead to a strong nonspecific induction of B-cell proliferation in 
bronchial tissue. This might lead to a rapid increase in the total serum IgE, as 
observed previously [195], and therefore can provide a synergistic link between 
allergy, HRV infection, and exacerbation of asthma [160]. Further, it would be 
interesting to examine whether infected B-cells become targets for other 
immune cells like natural killer or cytotoxic T-cells. 
 
 
Figure 8. The capacity of HRV to induce the proliferation of B cells. PBMCs were 
incubated with mock, HRV1b, HRV16, HRV14 and HRV29 (MOI = 1.0 or 10.0). 
Proliferation rate of B cells and CD8+ and CD4+ cells was measured by CFSE labeling 
assay and anti-CD4, anti-CD8 and anti-CD19 antibodies were used as discrimination 
markers. Time – 5th day after activation with HRV. Data are mean with confidential 
interval 95%. Statistical significance was determined using one-way ANOVA with 
Bonferroni’s multiple comparison test with **P < 0.01, *P < 0.05 from six different 
donors (paper I) [181]. Reprinted with permission of the John Wiley and Sons. 
Copyright © 2017 John Wiley and Sons. Aab A, Wirz O, van de Veen W, Söllner S, 
Stanic B, Rückert B, Aniscenko J, Edwards MR, Johnston SL, Papadopoulos NG, 
Rebane A, Akdis CA, Akdis M. 2017. Human rhinovirus forms viral replication centers 
in B cells and induces the proliferation of B lymphocytes. Allergy. 2017 Feb;72(2):232–
243. doi: 10.1111/all.12931 
 
5.2. Cultured primary airway epithelial cells associated 
with Th2-type cytokine-induced goblet cell metaplasia 
have decreased susceptibility to HRV-A16 infection 
Although numerous studies have aimed to describe the role of inflammatory 
responses of bronchial epithelial cells in asthma [143, 145–148], these studies 
do not fully agree with each other and many questions still remain. To describe 
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the responses of the epithelium, we used ALI cultures of bronchial epithelial 
cells from patients with asthma and control subjects to compare HRV16-
induced changes in mRNA expression of asthma candidate genes (paper II 
[183]). The experiments were performed in the presence or absence of IL-13, 
which induces mucus metaplasia.  
Interestingly, we identified ciliary cells as the main target for HRV16 by 
immunofluorescence imaging and demonstrated that the numbers of ciliary cells 
decreased in HRV16-infected epithelium also in the absence of IL-13 (figure 9). 
At the same time, mucus metaplastic epithelium was characterized by a 20-fold 
less replication of HRV16 (figure 2A in paper II [183]). This effect was seen to 
the same extent in patients with asthma and control subjects. 
 
 
Figure 9. Ciliated cells are the target for HRV16. A) Decrease in the percentage of 
ciliated cells in mucociliary epithelium (30-d culture) 48h after infection. **P<0.01. B) 
Percentage of ciliary cells in HRV16-infected or mock treated epithelium 48h after 
infection in different asthma severity groups. C) A representative composite image of 
HRV16-infected (8h) mucociliary epithelium stained with anti-HRV-VP2 antibody 
(red), antitubulin-βIV (green) and Hoechst (blue). Examples of HRV16 infected ciliated 
cells (arrows) and uninfected ciliated cell (arrowheads) are shown. D) A representative 
image of HRV16 infected (8h) mucus metaplastic epithelium anti-HRV-VP2 antibody 
(red) and MUC5AC (green). An exemplary HRV infected cell is noted with an arrow, 
MUC5AC-bright goblet cell (mucus granules) is noted with and arrowhead. E) Typical 
images of HRV16 infected ciliary cells (8h) after attachment of virus. F) Typical images 
of HRV16 infected ciliated cells (red) at 16h. Majority of cells are round shaped, with 
distorted or reduced cilia (green). G) Detached cells (and debris) in cytospin preparation 
of apical secretions collected 48h after infection with HRV16 (stained with May-
Grünwald-Giemsa). H) Example image showing HRV16 positive cells (red) and debris 
with cilia (arrowhead) in cytospin preparation of apical secretions (48h) (paper II) 
[183]. Reprinted with permission of the American Thoracic Society. Copyright © 2016 
American Thoracic Society. Jakiela B1, Gielicz A, Plutecka H, Hubalewska-Mazgaj M, 
Mastalerz L, Bochenek G, Soja J, Januszek R, Aab A, Musial J, Akdis M, Akdis CA, 
Sanak M. 2014. Th2-type cytokine-induced mucus metaplasia decreases susceptibility 
of human bronchial epithelium to rhinovirus infection. The American Journal of 
Respiratory and Critical Care Medicine; 51(2):229–41 
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To study changes in gene expression, we analyzed three groups of genes: 
inflammation-associated genes, genes involved in bronchial remodeling and 
eicosanoids. As expected, the expression changes were detected for the genes in 
the IFN and NF-κB pathways, including CXCL10, CXCL5 and STAT1 both in 
mucociliary differentiation (figure 10A, B) and mucous metaplastic condition 
(figure 10C, D). Altered expression of particular eicosanoids (PTGER2, PTGFR, 
LTC4S and ALOX15) was also observed in both conditions (figure 10).  
 
 
Figure 10. Gene expression in HRV16 infected ALI-differentiated airway epithelium. 
A) Scatter plot showing HRV-induced differences in gene expression determined at 24 
or 48 hours after infection (gray square indicates the area of no biological significance. 
Only selected genes are labeled. B and D) Table summarizing the differences in gene 
expression upon RV16 infection (48h incubation) of mucociliary (B) or mucus 
metaplastic (D) epithelium. For mucociliary differentiating conditions, human bronchial 
epithelial cells (HBECs) were cultured in the presence of IL-13 (5 ng/ml, days 22–26) 
and a combination of IL-13 and IL-4 (5 ng/ml, days 26–30). C) Scatter plot showing 
HRV-related differences in gene expression (48h incubation) in 30-day ALI cultures 
from non-asthmatic subjects and from patients with asthma (paper II) [183]. Reprinted 
with permission of the American Thoracic Society. Copyright © 2016 American 
Thoracic Society. Jakiela B1, Gielicz A, Plutecka H, Hubalewska-Mazgaj M, Mastalerz L, 
Bochenek G, Soja J, Januszek R, Aab A, Musial J, Akdis M, Akdis CA, Sanak M. 2014. 
Th2-type cytokine-induced mucus metaplasia decreases susceptibility of human 
bronchial epithelium to rhinovirus infection. The American Journal of Respiratory and 
Critical Care Medicine; 51(2):229–41 
46 
When the expression levels of these genes in HRV16-infected mucociliary 
epithelium were compared with mucous methaplastic epithelium, the over-
expression of genes associated with bronchial remodeling (e.g., MUC5AC and 
FGF2) and altered expression of eicosanoids was observed (figure 11). 
  
 
Figure 11. Comparison of HRV16-induced gene expression changes in HBEC cells 
cultured in mucus metaplasia or mucociliary differentiation conditions. A) Table 
summarizing the differences in gene expression in airway epithelium upon induction of 
mucus metaplasia as compared to mucociliary differentiation conditions. Only genes 
significantly (t test, P<0.05) up-regulated (with RQ > 2-fold, green) or down-regulated 
(with RQ < 2-fold, red) upon Th2-type cytokine treatment are marked (*not detected). 
B) Correlation of the number of ciliary cells per mm2 with relative expression of dynein 
chain (DNAH9) and the number of goblet cells per mm2 with mucin-5AC (MUC5AC). 
DNAH9 and MUC5AC relative expressions are normalized to 18S rRNA (in gene 
expression analyses). C) Scatter plot showing changes in gene expression (RQ) in 
airway epithelium related to mucus metaplasia (gray square indicates the area of no 
biological significance) in asthmatic and non-asthmatic patients (paper II) [183]. 
Reprinted with permission of the American Thoracic Society. Copyright © 2016 
American Thoracic Society. Jakiela B1, Gielicz A, Plutecka H, Hubalewska-Mazgaj M, 
Mastalerz L, Bochenek G, Soja J, Januszek R, Aab A, Musial J, Akdis M, Akdis CA, 
Sanak M. 2014. Th2-type cytokine-induced mucus metaplasia decreases susceptibility 
of human bronchial epithelium to rhinovirus infection. The American Journal of 
Respiratory and Critical Care Medicine; 51(2):229–41 
 
In addition, arachidonic acid–derived eicosanoids were measured in basolateral 
supernatants from mock-treated or HRV16-infected (48h) airway epithelial cells 
cultured either in mucus metaplasia or mucociliary differentiation conditions 
(figure 12). In both conditions, the concentration of particular arachidonic acid–
derived eicosanoids and prostaglandins was increased upon infection with 
HRV16.  
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Figure 12. Changes in lipidomic profile after HRV16 infection of in vitro differentiated 
airway epithelium. A) Arachidonic acid–derived eicosanoids were measured in 
basolateral supernatants from mock-treated or HRV16-infected (48h) airway epithelial 
cells cultured for 30 days in ALI. Horizontal bars represent medians. *P<0.05; 
**P<0.01. B). Scatter plot showing fold-change in concentration of eicosanoids after 
HRV16 infection in mucociliary differentiated epithelium. Results from patients with 
asthma and non-asthmatic subjects are contrasted. Area of no biological significance is 
marked in gray. Prostaglandins are encircled with a dashed line. C) Scatter plot showing 
fold changes in eicosanoid concentration in HRV-infected mucus metaplastic epithelium. 
Results from patients with asthma and non-asthmatic subjects are contrasted. Area of no 
biological significance is marked in gray. Prostaglandins are encircled with a dashed 
line (paper II) [183]. Reprinted with permission of the American Thoracic Society. 
Copyright © 2016 American Thoracic Society. Jakiela B1, Gielicz A, Plutecka H, 
Hubalewska-Mazgaj M, Mastalerz L, Bochenek G, Soja J, Januszek R, Aab A, Musial 
J, Akdis M, Akdis CA, Sanak M. 2014. Th2-type cytokine-induced mucus metaplasia 
decreases susceptibility of human bronchial epithelium to rhinovirus infection. The 
American Journal of Respiratory and Critical Care Medicine; 51(2):229–41 
 
According to these results, we speculate that increased release of prostaglandins 
associated with HRV infection may contribute to the overproduction of mucus 
and facilitate the development of mucus metaplastic phenotype of airway 
epithelium [147].  
Although alterations in inflammatory responses of bronchial epithelial cells 
from asthmatic patients are described before [168], in this study, we could not 
detect significant differences in gene expression pattern and lipidomics of 
HRV16A infected epithelial cells from control subjects versus asthmatic 
patients. Similar trends in the gene expression changes in patients with asthma 
and non-asthmatic subjects were observed (figure 10C, 11C and 12B, C). 
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5.3. Possible mechanisms of virus induced asthma 
exacerbation 
Asthma is a very diverse and individual condition where personal risk factors 
shape the severity of the disease. Environmental factors like pollutants, irritants, 
and allergens, might promote the exacerbation of the disease.  
In addition, it seems that, there is an additive and/or synergistic effect 
between allergic sensitization and viral illnesses often leading to greatly increased 
severity of asthma symptoms [161]. Principal site for HRV infection is URT 
epithelial cell lining [197]. However, more than 50% of bronchial epithelial 
biopsies collected from patients during virus-induced asthma exacerbation have 
found to be HRV positive [198]. It is known that the HRV infections enhance 
allergic inflammation in airways [141, 199–201], suggesting that non-adequate 
responses of lymphocytes might also contribute to the exacerbated inflammatory 
condition. Especially among children, the most exacerbation-prone subgroup of 
patients is highly atopic, with high IgE and eosinophilia. Accordingly, a very 
recent study demonstrates that in this subgroup, seasonal treatment with 
omalizumab decreased the duration of HRV infections and the risk of HRV-
induced illnesses [202]. These findings indicate that there is a clear link between 
the atopy and HRV-induced asthma exacerbation as blocking of IgE decreases 
susceptibility to HRV infections and illnesses. 
Here we were interested whether HRV has particular properties that are 
shaping non-adequate immune responses. As a novel idea, we investigated the 
ability of HRVs to bind and activate lymphocytes using in vitro cultured 
PBMCs. We were able to show that indeed monocytes, CD4+ T-cells, CD8+ T-
cells and B-cells interact and respond to HRV. More importantly, we found that 
the activation of B-cells by HRVs is time- and viral concentration- dependent, 
which raises a question about the nature of the interaction of HRV with B cells. 
Is HRV able to infect B-cells or/and is it possible that the shape and size of HRV 
virion can induce BCR crosslinking and this way activate the B-cells? Does the 
activation of the B-cells somehow cause a switch of B-cell type, for example to 
produce more IgE? Further studies are needed to answer to these questions.  
It has been suggested that HRV might increase the severity of asthma by 
damaging bronchial epithelium, which is followed by non-adequate inflam-
matory responses and secondary dysfunction of the airways. However, as HRVs 
generally infect a small number of airway epithelial cells, it is very unlikely that 
the biggest contributor for asthma exacerbation is the HRV infection itself and 
rather it is the inflammation induced by the infection. Several studies have 
shown that HRV induces acute-phase cytokines, such as IL-1β and type I and 
III interferons [165, 166] and mediators (prostaglandins, kinins) that can 
damage bronchial epithelium or induce secretion of chemokines and mediators 
of inflammation [203, 204]. In the later stage of infection, HRV might also 
induce mucus secretion [205, 206]. 
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An interesting point to note is that respiratory allergies seems to inhibit 
antiviral responses, as allergic asthma patients have been found to be more prone 
to HRV infection-related exacerbation of asthma [207, 208]. Some studies 
suggest that type 2 inflammation (e.g. ILC2 and Th2 cells controlled) could 
inhibit virus-induced interferon responses [163]. It is likely that for asthma 
outcome, the shape of virus-induced interferon responses is an important 
determinant. Too little interferon in the beginning of the viral infection probably 
allows more efficient viral replication, whereas excessive interferon secretion 
later might worsen the symptoms of the asthma [209–211]. At the time when, 
we started our experiments inducing PBMCs with HRVs, we were not aware of 
the fact that the activation of ILC2s by viruses can also facilitate Th2 type 
inflammation independent of adaptive immunity [212]. So, our finding that the 
HRV can induce B-cell proliferation without noticeable activation of CD4+ T 
cells might present another novel side of the story.  
Several other features of HRV infection in lower airways could enhance the 
severity of asthma. HRV infection stimulates mucus secretion, edema and 
bronchospasms. These effects contribute to airway narrowing and thereby 
increase a risk of exacerbation. Well-differentiated epithelium is relatively 
resistant to HRV infection [146], but impaired epithelium allows increased 
HRV replication allowing more severe HRV infection [147].  
Still, relationship between HRV infection and asthma exacerbation is poorly 
understood and has been mostly limited to epidemiological studies. As virus-
induced exacerbations are still one the major causes of morbidity and mortality 
among asthma patients, and HRVs are the most common triggering factors of 
acute asthma exacerbations [141, 213], further studies are needed to explore the 
role of HRV in the modulation of immune responses during asthma exacerbation. 
 
 
5.4. The level of miR-146a is increased in keratinocytes and 
skin from patients with atopic dermatitis  
MiRNAs are energetically effective way to manipulate with high precision 
cellular and immunological responses. Therefore, it has been suggested that 
miRNAs are used a lot by our organism to fine-tune the molecular responses to 
different challenges. Understanding the role of miRNAs in the regulation of 
molecular pathways might lead to better understanding of atopic and chronic 
inflammatory diseases.  
In the beginning of our studies, there was very little information available 
about the role of miRNAs in allergic diseases [214, 215]. We focused our 
studies on the role of miRNA-146a in the skin inflammation in AD as it was 
upregulated in cultured primary keratinocytes from patients with AD compared 
to cells from control subjects (figure 13A). We confirmed that miRNA-146a 
expression was increased both in nonlesional and lesional skin of patients with 
AD (figure 13B). In human keratinocytes form non-atopic donors, miRNA-146a 
was strongly upregulated by IL-1β, TNF-α, and IL-17A, with a synergistic 
50 
effect between the three cytokines (figure 13C) demonstrating that miRNA-146a 
is induced by proinflammatory cytokines and in the skin of patients with AD. 
 
 
Figure 13. miRNA-146a expression in the skin and keratinocytes. A) Heatmap of 
miRNAs that are differentially expressed in keratinocytes from patients with AD (AD1-
AD3) and healthy individuals (H1-H3). Log2 values of miRNA expression signals are 
mean-centered for each gene separately. Color scale from blue (lower) to red (higher) 
represents deviation from the mean (black). B) The relative miRNA-146a expression in 
lesional (L) and nonlesional (NL) skin of patients with AD compared with the mean of 
healthy (H) controls. C) miRNA-146a expression in keratinocytes from non-atopic 
donor stimulated or costimulated with indicated cytokines. Data on (C) are presented in 
log10 scale. Statistical analysis was performed relative to unstimulated control (cont) 
(*) or single treatments (#). Data are mean with SEM, **P < 0.01, *P = 0.01/0.05. 
(paper III) [184]. Reprinted with permission of the ELSEVIER. Copyright © 2016 
ELSEVIER. Rebane A, Runnel T, Aab A, Maslovskaja J, Rückert B, Zimmermann M, 
Plaas M, Kärner J, Treis A, Pihlap M, Haljasorg U, Hermann H, Nagy N, Kemeny L, 
Erm T, Kingo K, Li M, Boldin MP, Akdis CA. 2014. MicroRNA-146a alleviates 
chronic skin inflammation in atopic dermatitis through suppression of innate immune 
responses in keratinocytes. J Allergy Clin Immunol. 2014 Oct;134(4):836–847.e11. doi: 
10.1016/j.jaci.2014.05.022. 
 
 
5.5. miRNA-146a controls keratinocyte responses  
to IFN-γ and TNF-α  
To elucidate the role of miRNA-146a function in keratinocytes, we next 
overexpressed miRNA-146a in unstimulated and IFN-γ– or TNF-α–stimulated 
keratinocytes and performed mRNA array analysis (figure 14A). TNF-α was 
used as a strong stimulant of miRNA-146a and IFN-γ as a hallmark cytokine of 
chronic skin inflammation in AD known to cause global changes in gene 
expression in keratinocytes. The transfection of miR-146a resulted in down-
regulation of 102, 37 and 410 genes in unstimulated, TNF-α-stimulated and 
IFN-γ-stimulated keratinocytes, respectively (paper III, online repository figure 
E1). According to Targetscan 6.2 [103, 188], 21 predicted targets were 
suppressed by miRNA-146a in both IFN-γ–stimulated and unstimulated 
conditions, including the previously identified miRNA-146a direct targets IRAK1 
[216] and CARD10 [217]. miR-146a strongly inhibited chemokine signaling 
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pathway (figure 13A) and the NF-κB pathway (paper III, figure 2D, E). Among 
genes, suppressed by miR-146a, three genes: CCL5, UBD and IL-8 were 
observed to be increased in the skin of AD patients (paper III, figure 3A). 
Suppression of miR-146a direct targets, CARD10 and IRAK1 as well as miR-
146a influenced genes, CCL5 and IL-8, was confirmed by RT-qPCR (figure 
14B). Reduced amounts of CCL5 and CXCL10 in IFN-γ–stimulated, IL-6 in 
TNF-α– and IFN-γ–stimulated, and IL-8 in all conditions were detected in 
supernatants of keratinocytes on overexpression of miRNA-146a (figure 14C). 
Together, these results demonstrated that miR-146a inhibits the expression of 
numerous pro-inflammatory factors, including IFN-γ-inducible and AD-
associated genes CCL5, CCL8 and UBD in human primary keratinocytes. 
 
  
Figure 14. miRNA-146a inhibits the expression of NF-κB–dependent genes in primary 
keratinocytes (KCs). A–C) KCs were transfected either with control (cont) or pre-
miRNA-146a (miRNA-146a) for 24 hours and then stimulated with IFN-γ or TNF-α for 
48 hours or left unstimulated (us). Heatmap of the predicted direct targets. B) Relative 
mRNA expression for CCL5 is presented in log10 scale. C) Chemokine levels (pg/ml) 
in supernatants of keratinocyte cultures (n = 2). Data are represented as mean with 
SEM. Students t-test, * P < 0.05, **P < 0.01 (paper III) [184]. Reprinted with permission 
of the ELSEVIER. Copyright © 2016 ELSEVIER. Rebane A, Runnel T, Aab A, Mas-
lovskaja J, Rückert B, Zimmermann M, Plaas M, Kärner J, Treis A, Pihlap M, Haljas-
org U, Hermann H, Nagy N, Kemeny L, Erm T, Kingo K, Li M, Boldin MP, Akdis CA. 
2014. MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis 
through suppression of innate immune responses in keratinocytes. J Allergy Clin 
Immunol. 2014 Oct;134(4):836–847.e11. doi: 10.1016/j.jaci.2014.05.022. 
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To study how miRNA-146a affects AD-related inflammation in vivo, we used 
MC903-dependent mouse model of AD [218]. In this model, miR-146a was 
increased upon the treatment with MC903 in WT mice, whereas the direct 
targets of miR-146a, CARD10 and IRAK1 were downregulated in WT mice 
(figure 15A). In line with experiments in human keratinocytes, we observed 
increased mRNA expression of IFN-γ, CCL5, CCL8, and UBD in the skin of 
MC903-treated miR-146a−/− mice as compared to MC903-treated WT mice 
(figure 15B). These results demonstrate that in case of lack of miRNA-146a, 
there is increased inflammation in the skin in MC903-dependent mouse model 
of AD, which involves targeting of the NF-κB pathway-activating elements 
CARD10 and IRAK1 and suppression of the AD-related genes CCL5, CCL8, 
and UBD (figure 15B).  
 
Figure 15. Increased expression of proinflammatory cytokines in inflamed skin of 
miRNA-146a–deficient mice. WT and miRNA-146a−/− (146a−/−) mice were topically 
treated with MC903 or ethanol as a control (cont). A and B) The relative expression of 
miRNA-146a and mRNA levels compared with the WT cont. Data are represented as 
mean with SEM. Students t-test, * P < 0.05, **P < 0.01. (paper III) [184] Reprinted 
with permission of the ELSEVIER. Copyright © 2016 ELSEVIER. Rebane A, Runnel 
T, Aab A, Maslovskaja J, Rückert B, Zimmermann M, Plaas M, Kärner J, Treis A, 
Pihlap M, Haljasorg U, Hermann H, Nagy N, Kemeny L, Erm T, Kingo K, Li M, 
Boldin MP, Akdis CA. 2014. MicroRNA-146a alleviates chronic skin inflammation in 
atopic dermatitis through suppression of innate immune responses in keratinocytes. J 
Allergy Clin Immunol. 2014 Oct;134(4):836–847.e11. doi: 10.1016/j.jaci.2014.05.022. 
 
As we did not observe significant influence of miR-146a to Th2 type cytokines, 
such as TSLP and IL-4, in used mouse model of AD (paper III, online 
supplementary figure E4) ([181–184, 219], we propose that in this mouse model 
of AD, miRNA-146a mainly influences the chronic inflammation of AD. 
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Although shown previously in other cell types [220, 221], we could not see 
significant influence of miR-146a on JAK-STAT pathway as no reduction in 
phosphorylation of STAT1 was detected (paper III, figure 2E). As siRNA 
suppression of miR-146a direct targets from the NF-κB pathway (CARD10 and 
IRAK1) also inhibited AD-associated target genes upon stimulation of IFN-γ 
(paper III, figure 4), we propose that in keratinocytes, miR-146a primarily 
inhibits the activation of the NF-κB pathway. However, it is not clear, how  
IFN-γ activates the NF-κB pathway in keratinocytes. As the siRNA suppression 
of CARD10, but not IRAK1 affected CCL5 level upon stimulation by IFN-γ 
(paper III, figure 4), our results indicate, that the activation of the NF-κB 
pathway by IFN-γ involves CARD10 in keratinocytes.  
Still, multiple open questions remain. First, it is possible that miRNA-146a 
is involved in the suppression of Th2 responses because it has been show to 
down-regulate T cell receptor-driven NF-kB activation [222]. In addition, the 
effect of miR-146a on allergen-induced activation of dendritic cells and epithelial 
cells, as well as the impact on the immune responses caused by pathogens 
characteristic to AD, such as Staphylococcus Aureus, remain to be studied. 
Interestingly, our results suggest that manipulation of the NF-κB pathway 
through miRNA-146a might give us a potential treatment of chronic inflam-
matory conditions in the skin or even in the airways in the case of asthma. 
Recently, a well-known allergen, the house dust mite was shown to directly 
activate bronchial epithelial cells and cause airway inflammation in mice 
through one of the main targets of miR-146a, CARD10 [223]. In addition, 
CARD10 has been shown to function as an activating factor of the NF-κB 
pathway during viral infection [224]. These studies indicate that miR-146a 
might actually also inhibit initiation of allergic inflammation in the bronchial 
epithelium and suppress immune responses to the HRVs through targeting of 
CARD10. In conclusion, our results demonstrate that miR-146a inhibits innate 
immune responses in keratinocytes and suggest that overexpression of miR-
146a may be a potential treatment of chronic inflammatory conditions in the 
skin and perhaps also in other tissues.  
 
 
5.6. Increased IFN-γ and IFN-γ-inducible genes  
in atopic dermatitis skin might mediate  
enhanced apoptosis of keratinocytes 
Although Th2 type immune responses are considered more important in the 
triggering of AD, in the chronic phase of skin inflammation in AD, multiple 
types of immune cells and a mixture of pro-inflammatory cytokines strongly 
influence the disease pathogenesis [93, 225]. Among others, IFN-γ, IL-22 and 
TNF-α are widely known to be associated with chronic tissue inflammation. 
Besides other functions, IFN-γ is known to induce activation-induced apoptosis 
of keratinocytes in various skin diseases [225, 226]. Our aim was to investigate 
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whether intrinsic features of keratinocytes may be responsible for their 
increased apoptosis in AD. In addition, to find novel factors that might be 
responsible for keratinocyte apoptosis in the skin, we performed mRNA array 
analysis of skin biopsies and keratinocytes from AD patients.  
First, keratinocytes from AD patients and control individuals were studied 
for the activation-induced apoptosis caused by IFN-γ. Our results show that IFN-γ 
induced significantly more apoptosis of keratinocytes from patients with AD 
(27.1±13.8 % Annexin V positive cells) than keratinocytes from healthy subjects 
(15.4±3.8 % Annexin V positive cells) (figure 16A), suggesting that keratinocytes 
from patients with AD are more susceptible to IFN-γ–induced apoptosis. 
We next performed mRNA profiling of skin biopsies from AD patients with 
chronic AD lesions. Comparing the skin array results with a previously 
published dataset of IFN-γ–inducible genes from keratinocytes [227], we found 
9 overlapping genes, which indicates that gene expression changes in the skin 
indeed reflect the influence of IFN-γ (figure 16B). 
 
Figure 16. Increased IFN-γ stimulated apoptosis of AD keratinocytes and increased 
expression of IFN-γ–inducible genes in AD skin. (A) The viability of unstimulated 
(u.s.) or IFN-γ–stimulated keratinocytes was measured by staining with Annexin V and 
7AAD four days after the stimulation. The results are presented as mean ±SD (n=2). (B) 
Increased expression of IFN-γ–regulated genes in lesional skin from patients with AD. 
Venn diagram of the selection process and heat map of log2 values of selected 
differentially expressed genes (paper IV [182]). Reprinted with permission of the 
ELSEVIER. Copyright © 2016 ELSEVIER. Rebane A, Zimmermann M, Aab A, 
Baurecht H, Koreck A, Karelson M, Abram K, Metsalu T, Pihlap M, Meyer N, Fölster-
Holst R, Nagy N, Kemeny L, Kingo K, Vilo J, Illig T, Akdis M, Franke A, Novak N, 
Weidinger S, Akdis CA. 2012. Mechanisms of IFN-γ–induced apoptosis of human skin 
keratinocytes in patients with atopic dermatitis. J Allergy Clin Immunol. J Allergy Clin 
Immunol. 2012 May;129(5):1297–306. doi: 10.1016/j.jaci.2012.02.020 
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In addition, we performed mRNA array analyses of cultured keratinocytes from 
AD patients, which revealed differential expression of apoptosis-related genes 
in AD keratinocytes (paper IV, figure 3) [182]. Concordantly, three apoptosis-
related (NOD2, DUSP1 and ADM) and 8 genes upregulated in AD skin lesions 
(CCDC109B, CCL5, CCL8, IFI35, LYN, RAB31, IFITM1 and IFITM2) were 
observed to be induced by IFN-γ in keratinocytes, while Th2 type cytokine IL-4 
had no influence and TNF-α only moderately stimulated the expression of 
CCL5 (paper IV, figure 6 [182]). 
These results show that IFN-γ–inducible genes and apoptosis-related genes 
can be stimulated in AD skin, and thus might contribute to the disease related 
apoptosis, spongiosis and development of eczematous lesions in AD skin. 
Remarkably, although inflamed skin of AD patients has been shown to contain 
more Th2 type cells, and AD is known as Th2 type disease [228], we observed 
strong influence of IFN-γ on global gene expression pattern. It is possible that 
compared with other cytokines, IFN-γ is more powerful in the stimulation of 
inflammatory responses in keratinocytes, and, especially together with other 
cytokines, has a very strong effect even at relatively low concentrations produced 
by only a small fraction of IFN-γ–producing cells in the skin of AD patients.  
Interestingly, it has been shown recently that in psoriasis, which is charac-
terized with more intensive hyper-proliferation of keratinocytes and thickening 
of epidermis compared to AD, anti-apoptotic genes are overexpressed [229]. 
One probable explanation is that the presence of IFN-γ and apoptosis of 
keratinocytes might actually have protective role in the tissue, as apoptosis helps 
to clear damaged cells without increasing tissue inflammation and development 
of necrosis. A recent study using FAS-deficient mice as a model of AD 
demonstrated that in case of reduced apoptosis, the inflammation and changes 
in the epidermis are stronger, which indicates that apoptosis is beneficial for 
recovery [230].  
It is also interesting that increased IFN-γ–induced apoptosis and differences 
in mRNA and miRNA (paper III [184]) expression profile of keratinocytes from 
AD patients can be detected even after several passages of keratinocytes in 
tissue culture. This hints at the underlying genetic differences or epigenetic 
changes, which take place in keratinocytes during the disease, and can persist 
over extended time scales sufficient to maintain chronic inflammatory state.  
In conclusion, we propose that differentially-expressed apoptosis-related and 
IFN-γ–inducible genes, or both in keratinocytes identified herein might be 
involved in the pathogenesis of AD. However, it is not entirely clear, whether 
the increased expression of IFN-γ–inducible genes and related apoptosis of 
keratinocytes contribute to the long-lasting inflammation in AD, or if they are 
the signs of the recovery. 
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CONCLUDING REMARKS 
Within the current thesis, four studies exploring different aspects in the 
molecular background of AD and asthma were carried out.  
First, we found that beside the epithelial cells, HRV might actively interact 
with monocytes, CD4+ T cells, CD19+ B cells, and CD8+ T cells. More 
importantly, we show for the first time that HRVs enter and can induce the 
proliferation of CD19+ B cells. These results indicate that in allergic/asthmatic 
individuals, HRVs can infect not only LRT epithelial cells but also underlining 
infiltrating immune cells in the inflamed epithelium, which possibly may lead to 
a nonspecific induction of B-cell proliferation in bronchial tissue, a rapid 
increase in the total serum IgE, and therefore, can provide a synergistic link 
between allergy, HRV infection, and exacerbation of asthma. Thus, our results 
demonstrate that for understanding HRV-induced asthma exacerbation, we need 
to take a much broader approach to the problem than has been taken so far, and 
also give further consideration to the participation of immune system. 
It is known that HRV infects a rather small number of respiratory epithelial 
cells. However, this phenomenon remains poorly-explained. In paper II, we 
studied more closely the ability of HRV to infect different types of respiratory 
epithelial cells and found that HRV preferentially infects ciliated epithelial 
cells. We observed that HRV16 infection led to a significant disappearance of 
ciliated cells from airway epithelium due to detachment of the cells. Because 
the epithelium in asthma is already compromised, HRV infection may aggravate 
a deficiency in mucociliary clearance due to preferential loss of ciliary cells and 
hypersecretion of mucus, both factors known for their detrimental impact on the 
function of the airways. 
In paper III, we aimed to study the function miRNAs in AD. We found that 
miR-146a expression was increased in keratinocytes and lesional skin of 
patients with AD. In human primary keratinocytes, miRNA-146a was able to 
inhibit the expression of IFN-γ–inducible and AD associated genes IL-8, CCL5, 
CCL8, and UBD. In addition, miR-146a–deficient mice had elevated expression 
of the same factors in the skin as those of a MC903-dependent mouse model of 
AD. Considering that IFN-γ and the activation of the NF-κB pathway are both 
characteristic of chronic skin inflammation in AD, our results demonstrate that 
miR-146a has an anti-inflammatory function in the chronic AD skin. Our data 
also suggest that manipulation of the NF-κB pathway through miRNA-146a 
might give us a potential treatment for chronic inflammatory conditions in the 
skin (or even in airways in case of asthma), as the NF-κB pathway is also 
activated in tissues in other chronic inflammatory diseases and during viral 
infection.  
Finally, in paper IV, we show the increased expression of IFN-γ–inducible 
genes in the skin and apoptosis-related genes in the keratinocytes from AD 
patients. Together with the result demonstrating the increased IFN-γ–induced 
apoptosis of keratinocytes from AD patients, our data suggest that besides Th2 
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type immune responses and cytokines, multiple other disease-related factors 
impact pathogenesis of AD. It was also interesting to observe that keratinocytes 
from AD patients showed differences in miRNA and mRNA expression 
compared to keratinocytes from control subjects even after several passages in 
tissue culture. This indicates that epigenetic changes might take place in cells 
affected by the diseases and these changes might affect the development of 
chronic conditions. Obviously, further studies are needed to explore epigenetic 
changes and their impact on chronic diseases, including AD and asthma.  
In conclusion, our work describes multiple aspects at the molecular level in 
association with asthma and AD. Definitely, we have now a better under-
standing of the molecular mechanisms of asthma and AD. However, con-
sidering the striking heterogeneity of these diseases, which is exemplified by 
variations in clinical features, and individual risk factors and shown by the 
absence of reliable biomarkers, diagnostic tests, or specific treatments that 
would apply to all patients, many questions still remain to be answered.  
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CONCLUSIONS 
1. Besides epithelial cells, HRVs have capacity to interact with monocytes, 
CD4+ T cells, CD19+ B cells, and CD8+ T cells. HRVs are able to infect 
and induce the proliferation of CD19+ B cells. These results indicate that 
HRVs may cause a nonspecific induction of B-cell proliferation in bronchial 
tissue, which might contribute to the exacerbation of asthma.  
2. In in vitro differentiated bronchial epithelium, HRV16 preferentially infects 
and causes significant disappearance of ciliated cells. The infection with 
HRV16 causes changes in the expression of genes from the NF-κB pathway 
and upregulates interferon-inducible genes. HRV16 infection of mucociliary 
epithelium induced overexpression of genes associated with bronchial 
remodeling (MUC5AC, FGF2, and HBEGF), induction of cyclooxygenase-2, 
and increased secretion of prostaglandins. 
3. miR-146a has increased expression in the skin of patients with AD and 
inhibits multiple factors from the NF-κB pathway, including IL-8, CCL5, 
CCL8, and UBD in keratinocytes and in a mouse model of AD. Therefore, 
we conclude that miR-146a has an anti-inflammatory function in the chronic 
inflammation in AD skin.  
4. Increased expression of IFN-γ–inducible genes detected in the chronic skin 
lesions of AD patients and increased IFN-γ–induced apoptosis of cultured 
keratinocytes from AD patients may contribute to the long-lasting skin 
inflammation in AD.  
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FUTURE PROSPECTS 
The data accumulated during recent years have led to a huge progress in our 
understanding of the environmental, genetic, tissue-specific and immunological 
factors mastering the inflammatory conditions in AD and asthma. Our own 
research results about capacity of HRVs to directly affect immune cells and 
about miR-146a as a suppressor of chronic inflammation in AD suggest new 
approaches for studying these diseased conditions, as well as hint at the possible 
future treatment approaches. In addition, recent studies by others suggest that 
we need to consider more about the surrounding environment. It certainly seems 
very important to take care of microbiome around us to maintain healthy and 
supportive environment. We also need to develop new ways for managing, 
treating, and, in the future, preventing these disorders. In addition to molecular 
studies similar to those described here, we also need to continue with the long-
term longitudinal studies of phenotype, and integrate clinical and molecular data 
to effectively help patients with chronic inflammatory lung and skin diseases. In 
the near future, we are likely to be able to target more specifically the mediators 
of inflammatory diseases at the immune system level through the receptors, 
FcεRI for IgE triggering cytokines or effector cells in each particular case. This 
will be associated with the discovery of novel biomarkers, either proteins, 
mRNA or miRNAs that will help to better classify the patients. The new 
knowledge gained through all of our work would probably allow us also to 
prevent initial allergic sensitization, or induce safer forms of allergen-specific 
immunotherapy in the future, or perhaps even, for example, to use miRNAs as 
effective means to induce and maintain healthy immune responses. Time will 
tell us how successful we will be in managing these complex “disorders of 
advanced civilization”. 
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SUMMARY IN ESTONIAN 
Ülevaade astma ja atoopilise dermatiidi molekulaarsetest 
mehhanismidest 
Vaatamata edusammudele atoopilise dermatiidi (AD) ja astma tekkepõhjuste 
uurimisel, on saadud eksperimentaalsete tulemuste tõlgendamine ja rakenda-
mine kliinilisse praktikasse osutunud oodatust raskemaks. Üheks põhilisteks 
patoloogiateks AD ja astma korral on vastavalt kas epidermise või epiteeli 
struktuursed muutused. Kuid kuidas need muutused on seotud neid esile 
kutsuvate molekulaarsete mehhanismidega, pole meile veel kahjuks piisavalt 
selge. See omakorda pole võimaldanud patsiente kõige optimaalsemal moel 
ravida. Ilmselt tuleks nende krooniliste põletikuliste haiguste molekulaarsetest 
tekkepõhjustest arusaamiseks kasutada senisest veelgi uudsemaid lähenemisteid 
ja uurimismeetodeid.  
Üheks meile huvipakkuvaks teemaks oli uurida inimese rinoviiruse (HRV) 
nakkuse võimlikku osa astma ägenemise esilekutsumises. Kuigi HRV nakkuse 
põhiliseks märklauaks on hingamisteede epiteelirakud, siis oma töös me näita-
sime, et astma ägenemise põhjuste selgitamisel oleks oluline uurida ka HRV osa 
monotsüütide, CD4+ T, CD8+ T ja B-rakkude aktiviseerimisel. Samuti õnnestus 
meil esmakordselt näidata, et HRV viirus on võimeline nakatama B-rakke, seda 
küll in vitro tingimustes. Uus ja oluline avastus meie poolt on, et HRV võib 
esile kutsuda T-rakkudest sõltumatu mittespetsiifilise B-rakkude paljunemise. 
Kas selline protsess omab tegelikku rolli B-rakkude massilisel infiltreerumisel 
epiteelikoesse nagu see on täheldatav astma ägenemisega patsientide kopsu-
biopsia lõikudes, vajab veel edaspidist uurimist. Ülalmainitud protsessid võivad 
viia allergeen-spetsiifiliste B-rakkude paljunemisele ja seekaudu IgE oluliselt 
suurenenud kontsentratsioonile, mida on täheldatud HRV poolt esilekutsutud 
astma ägenemiste korral. See võib olla seletuseks, kuidas HRV nakkuse mõjul 
atoopilised põletikulised protsessid võivad kiiresti ägeneda.  
On teada, et HRV nakatab ainult väga väheseid epiteelrakke (1 – 5%) ja meil 
õnnestus oma töös jõuda lähemale selle fenomeni selgitamiseni. Nakatades 
erinevaid tüüpi juhtehingamisteede epiteelrakke, õnnestus meil näidata, et HRV 
nakatab eelistatult ripsepiteeli rakke. Ripsepiteeli rakkude hävimine võib olla 
põhjuseks, miks HRV nakkuse korral mükotsiliaarne puhastumine on pärsitud. 
Lisades suurenenud limaerituse, saame olukorra, mis on iseloomulik astma 
ägenemisele, kus peale põletikuliste protsesside on halvenenud ka mehaaniline 
lima eemaldamine bronhidest. 
Need avastused on viinud meie arusaamise oluliselt edasi viirusliku astma 
ägenemise protsessi mõistmisel ja andnud uued teaduslikud suunad nende prot-
sesside uurimiseks.“Allergilise marsi” hüpotees seob omavahel astma ja AD. 
Epidemioloogistest andmetest on täheldatud, et AD on esmaseks põletikuliseks 
haiguseks, mis paljudel juhtudel võiks olla astma tekkimise eelduseks hilisemas 
vanuses. Nende mõlema kroonilise põletikulise haiguse kulus ja molekulaar-
setest mehhanismides on palju sarnast. Selgusetu on veel, kas üks põhjustab 
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teist või kas inimestel kellel on soodumus üheks on soodumus ka teiseks allergi-
liseks haiguseks. 
Seoses AD-ga uurisime oma töös kahte molekulaaarset aspekti: kirjeldasime 
miR-146a funktsioone keratinotsüütides ja mõju hiire AD mudelis ning kirjel-
dasime võimalikke IFN-γ–indutseeritud kertinotsüütide apoptoosi põhjuseid.  
Oma uurimisobjektiks valisime miRNA-146a, kuna leidsime mikrokiibi 
tulemuste analüüsist, et miRNA-146a ekspressioon oli suurenenud AD patsien-
tide keratinotsüütides ja nahas. Oma töös näitasime, et miRNA-146a inhibeerib 
IFN-γ–indutseeritavaid ja AD seonduvaid molekule – IL-8, CCL5, CCL8, ja 
UBD, millede ekspressioni aktivatsioon on sõltuv NF-κB signaalirajast. Lisaks 
rakendasime atoopilise dermatiidi mudelit metsikut tüüpi ja miR-146a–/– hiir-
tele, et välja selgitada, kas miR-146a võib omada mõju AD tekkele organismi 
tasemel. Meie katsed näitasid, et samad NF-κB signaalirajast sõltuvad proinf-
lammatoorsed geenid, mis olid inhibeeritud miR-146a poolt inimese keratinot-
süütides, olid mõjutatud ka hiire AD mudelis. Arvestades, et nii IFN-γ kui ka 
NF-κB raja aktiveerumine on iseloomulik kroonilisele AD-le, näitavad meie 
tulemused, et miRNA-146a võib omada AD haigete nahas põletikuvastast 
toimet haiguse kroonilises faasis. Oletame, et miR-146a võiks olla potent-
siaalselt kasutatav ka krooniliste põletikuliste protsesside ravis. 
Käesoleva doktoritöö neljandas artiklis leidsime, et IFN-γ–indutseeritud 
apoptoos on tugevamini avaldunud keratinotsüütides, mis pärinevad AD pat-
sientidel võrreldes tervetest isikutest pärit keratinotsüütidega. Lisaks kirjel-
dasime geeniekspressiooni muutusi AD patsientide nahas ja keratinotsüütides. 
Nägime, et AD patsientidest pärinevatel keratinotsüütidel on mRNA ekspres-
sioonis muutused toimunud apoptoosiga seotud geenides ning, et atoopilise 
dermatiidi haigete nahas on muutunud IFN-γ poolt mõjutatavad geenid. Nende 
tulemuste põhjal võib oletade, et lisaks Th2-tüüpi põletikule, mõjuavad AD 
patogeneesi ka teised bioloogilised protsessid koes.  
Kokkuvõtteks võib öelda, et oma töös oleme käsitlenud mitmeid astma ja 
AD-ga seotud molekulaarseid aspekte. Kindlasti teame me nüüd rohkem fakto-
ritest, mis on nende haigustega seotud, kuid on liiga vara öelda, et me mõistame 
täielikult ja piisavalt põhjusi, mis viivad iga konkreetse patsiendi puhul haiguse 
tekkeni. Samuti ei ole olemas ühtset raviskeemi, mis ühtviisi hästi mõjuks 
kõigile haigetele. Eelkõige on ebapiisavate teadmiste põhjuseks nende haiguste 
endi suur heterogeensus, mis väljendub näiteks ka juba kliinilise pildi mitme-
kesisuses. Neil haigustel on ilmselgelt olemas alamtüübid, mis on reguleeritud 
erinevate molekulaarsete mehhanismide poolt, mis mõjutavad erineval määral ja 
viisil immuunvastuste individuaalset kujunemist. Endiselt on palju tööd, et aru 
saada AD ja astma molekulaarsetest põhjustest, et leida biomarkereid, mis 
aitaksid grupeerida patsiente ning parandada ravi ja mõista keskkonna fakorite 
mõju, et vältida neid haigus.  
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